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Abstract 
The search for novel candidate genes determining antidepressant treatment response 
received a lot of attention within the last decade. In times of genome wide association 
studies, a lot of effort was done to detect key target gene that are involved in 
antidepressant treatment outcome. However, the search for such central target genes that 
modulate antidepressant treatment outcome was rather disappointing. In the current 
thesis, we established a novel unbiased experimental approach to investigate individual 
antidepressant response in mice and furthermore tried to link these findings to the clinical 
situation. In a translational approach, we were able to identify novel target genes that are 
modulated after chronic antidepressant treatment. In a second step, we also investigated 
early antidepressant response within this approach, which is in line with the human early 
response following antidepressant treatment. Here, our main focus was placed on the 
analysis of a gene expression profile in the peripheral blood, which allowed us to integrate 
our findings with the human data set. This integration enabled us to predict antidepressant 
response within a subset of patient. Even more, we could find commonly regulated 
transcription factors in both species which may play a role in antidepressant response. 
Additionally, to these interesting findings we also investigated novel candidate genes that 
were regulated after chronic paroxetine treatment. One of the detected genes was Sox11, 
which was found to be upregulated after subchronic as well as chronic antidepressant 
treatment. We could show that Sox11 is mainly regulated in a time dependant manner via 
SSRIs. After various manipulations of Sox11, we could also demonstrate that Sox11 plays 
a crucial role in anxiety-related behavior and is thus a very promising candidate for further 
anxiety-related studies. 
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Zusammenfassung 
In den letzten Jahren wurden eine Reihe an Studien veröffentlicht deren Ziel es war, neue 
Kandidatengene mit einer potentiellen Rolle im Behandlungserfolg von Antidepressiva zu 
detektieren. In Zeiten von genomweiten Assoziationsstudien wurde die Suche nach 
Genen die einen Behandlungserfolg vorhersagen könnten, immer populärer. Trotz all der 
Bemühungen in den letzten Jahren, waren diese Studien jedoch überwiegend 
enttäuschend. In der vorliegenden Arbeit haben wir in einem neuen, 
unvoreingenommenen, experimentellen Ansatz versucht, individuelle Antidepressiva 
Responsivität in Mäusen zu modulieren. Darüber hinaus haben wir diese präklinischen 
Befunde mit Ergebnissen aus humanen Studien integriert. Durch diesen translationalen 
Ansatz waren wir in der Lage, neue Kandidatengene zu identifizieren, welche nach einer 
chronischen Antidepressivagabe reguliert werden. Neben der chronischen 
Verabreichungsdauer waren wir auch an einem subchronischen Verabreichungszeitpunkt 
interessiert.  Dieser Zeitpunkt war für uns von großem Interesse, da auch in klinischen 
Studien Untergruppen von sogenannten frühen Respondern  identifiziert werden konnten. 
Deshalb untersuchten wir im peripheren Blut das Genexpressionsprofil in den 
Respondersubgruppen und verglichen diese mit den Humandaten. Durch diesen Ansatz 
war es möglich Responsivität in Humandaten vorherzusagen. Des Weiteren wurden neue 
Kandidatengene untersucht, welche durch Verabreichung von Antidepressiva reguliert 
werden. Eines dieser Gene ist Sox11, welches nach subchronischer und chronischer 
Antidepressivagabe, primär durch Serotonin-Wiederaufnahmehemmer, reguliert wird. 
Nach genetischer Manipulation von Sox11 konnten wir zeigen, dass es eine zentrale Rolle 
in angstbezogenem Verhalten spielt. Dies macht Sox11 zu einem sehr 
vielversprechenden neuen Kandidaten für Studien die sich mit Angsterkrankungen 
befassen. 
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1 Introduction 
1.1 Depression 
“Mental pain is less dramatic than physical pain, but it is more common and also more 
hard to bear. The frequent attempt to conceal mental pain increases the burden: it is 
easier to say “My tooth is aching” than to say “My heart is broken.” (C.S. Lewis, The 
Problem of Pain). 
Major depressive disorder (MDD) is one of the most common mental disorders. It is a very 
complex and multifactorial psychiatric disease, which affects up to 20% of the general 
population (Kessler et al., 2005). Furthermore, unipolar depressive disorders place an 
immense burden on society and the World Health Organization (WHO) ranked depression 
as the fourth leading cause of disability (Murray and Lopez, 1996; Rubinow, 2006). 
Depression is different from normal sadness. It is a recurring, severe mental disorder with 
a high complexity of symptoms, as depressed mood, avolition, sleep or psychomotoric 
disturbances, anhedonia, dysregulation of metabolism, endocrine and inflammatory 
parameters, impaired cognitive performance and finally may also lead to suicide (reviewed 
in (Villanueva, 2013; Pae and Patkar, 2013; Nestler et al., 2002a)). Additionally, bipolar 
disorders (episodes of major depression and mania) and anxiety are two diseases that 
most frequently overlap diagnostically with depression (Flint and Kendler, 2014). 
Specifically, various studies could demonstrate that about 60% of the depressed patients 
report one or more anxiety disorders throughout their lives (reviewed  in (Flint and 
Kendler, 2014)). 
Despite tremendous efforts over the past decades to understand the molecular 
underpinnings of depression, the neuropathology of depression remains largely unknown. 
Various hypotheses have nevertheless been postulated to explain depression and the 
treatment of depression.  
Monoamine theory of depression 
In the 1960s, monoamine oxidase inhibitors (MAOIs) were found to effectively treat 
depressive disorders. As their pharmacological mechanism of action comprises the 
inhibition of monoamine reuptake, namely serotonin (5-HT) and norepinephrine (NE), 
Schildkraut and colleagues introduced the monoamine hypothesis of depression, in which 
a deficiency of monoamines is responsible for depression (Schildkraut, 1965). Although 
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this hypothesis is nearly 50 years old, today’s antidepressants are still designed to acutely 
increase monoamine transmission by either inhibiting the degradation or the neuronal 
reuptake of monoamines (reviewed in (Krishnan and Nestler, 2008)). However, the validity 
of the monoamine hypothesis and whether an imbalance of monoamines in fact underlies 
depression has been frequently questioned. MAOIs and serotonin reuptake inhibitors 
(SSRIs) produce immediate effects on monoamine transmission, whereas their effects on 
the improvement of depressive symptoms require weeks of treatment (Krishnan and 
Nestler, 2008). The monoamine hypothesis of depression still underlies the first-line 
therapy for treating depressed patients, however the delayed onset of action as well as 
the low remission rates of antidepressants (Trivedi et al., 2006) have encouraged 
scientists to search for alternative explanations. 
Dysfunction of the neuroendocrine and immune system in depression 
Another well-established model of depression comprises the dysfunction of the 
hypothalamic-pituitary-adrenal (HPA) axis in depressed patients (Holsboer, 2000). Acute 
as well as chronic physical and psychological stressors are potential activators of the HPA 
axis (Keeney et al., 2006). Stress-related inputs converge in the paraventricular nucleus of 
the hypothalamus, where neurons synthesize corticotropin-releasing hormone (CRH), 
arginine vasopressin (AVP) and other neuropeptides. This in turn stimulates the synthesis 
and release of adrenocorticotropic hormone (ACTH) from the anterior pituitary. ACTH 
subsequently activates the synthesis and the release of glucocorticoids (cortisol in 
humans and corticosterone in rodents) from the adrenal cortex. This synthesis and 
release leads to hormonal, autonomic and behavioral effects, which allow the system to 
adapt to an acute challenge (e.g. effects on metabolism). Therefore, it can be stated that 
the HPA axis is a key component of the stress response and thus an important regulator 
of various higher brain structures including the amygdala and hippocampus (Nestler et al., 
2002a; Holsboer, 2001). The release of glucocorticoids is essential as they are 
responsible for the regulation of the HPA axis via a negative feedback loop (Nestler et al., 
2002a). Healthy individuals can adapt to these changes, whereas depressed patients fail 
to adapt (de Kloet et al., 2005). It has been suggested that the sustained increase in 
glucocorticoid levels (e.g. after severe stress or trauma) may damage the hippocampus, 
specifically the neurons within the cornu ammonis region 3 (CA3), to facilitate 
dysregulation of the feedback system, whereby the negative feedback loop becomes a 
positive feedback loop. This positive feedback loop consequently promotes greater 
increase in circulating glucocorticoids and thus more damage (Holsboer, 2000). To 
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support this theory, clinical studies have challenged the neuroendocrine system, to 
demonstrate that a subset of depressed patients show disturbed HPA axis regulation. 
Moreover, post-mortem studies could demonstrate that an elevation of neuropeptides, 
such as CRH and AVP, is common in a subset of patients (reviewed in (de Kloet et al., 
2005)).  
Cytokines, hormonal mediators of the immune response, are also a crucial part of the 
neuroendocrine system and accordingly play an important role in mood disorders 
(Schiepers et al., 2005; Raison et al., 2006; Miller et al., 2009). As afore mentioned, 
elevated levels of glucocorticoids is a characteristic feature of depression in a subset of 
depressed patients. Normally, glucocorticoids promote potent anti-inflammatory effects. 
Depressed patients show high levels of circulating proinflammatory cytokines, such as 
interleukin-6 (IL-6) and tumor necrosis factor alpha (Villanueva, 2013; Dunn, 2000; Dunn, 
2006) to offset the elevated levels of glucocorticoids. Proinflammatory cytokines not only 
contribute to the innate immune response and inflammation, but they also have relevant 
neuroendocrine and metabolic effects, including neurotransmitter metabolism and neural 
plasticity (Villanueva, 2013). Preclinical studies have shown that administration of Il-6 
induces depressive-like behavior in rodents and furthermore neutralizes the 
antidepressant effects of fluoxetine (Sukoff Rizzo et al., 2012). This has been supported 
by a clinical study in which people were treated with interferon alpha and consequently 
developed depression (Shelton and Miller, 2010). Furthermore, post-mortem brain studies 
have shown that different cytokines and genes involved in apoptotic processes are 
upregulated in depressed patients (Shelton et al., 2011). Interestingly, cytokines also 
stimulate the HPA axis and activate the secretion of growth hormone (Leonard, 2000), all 
endocrine processes associated with depression (Villanueva, 2013). Nevertheless, results 
have been inconsistent when investigating serum cytokine concentrations in depressed 
patients, suggesting that immune activation only accounts for a small subset of patients 
(Krishnan and Nestler, 2008).  
Neurogenesis and depression 
Adult neurogenesis has drawn a lot of attention in neuroscience within the last years. It 
has been shown that the adult mammalian brain is still able to remove existing glia cells 
and neurons as well as establish novel neural circuits (Villanueva, 2013). Adult 
hippocampal neurogenesis describes the process by which neuronal progenitor cells of 
the hippocampal subgranular zone (SGZ) and the subventricular zone (SVZ) of the lateral 
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ventricles divide mitotically to form new neurons that differentiate and integrate into the 
dentate gyrus (DG) or the olfactory system (reviewed in (Krishnan and Nestler, 2008)). 
Gould and colleagues were the first to suggest a potential role of SGZ neurogenesis in 
mood regulation. They clearly demonstrated that corticosteroid administration results in 
the suppression of cell division in the SGZ (Gould et al., 1992). Subsequent animal 
studies effectively demonstrated that a variety of chronic stress paradigms, commonly 
used as a preclinical model of depression, lead to a reduction in cell proliferation (Mirescu 
and Gould, 2006). However, studies investigating the effects of acute stress are not 
completely in line with those examining chronic stress. Acute foot shock, for example, was 
shown to reduce cell proliferation in male rats, whereas acute restrained stress had no 
influence on cell proliferation (reviewed in (Zhao et al., 2008)). In contrast to these 
findings, the regulation of cell survival after stress is not completely understood (Zhao et 
al., 2008). Increased glucocorticoid levels are considered the central mechanism 
underlying stress-induced suppression of cell proliferation in the SGZ. This hypothesis 
could be supported by two main findings. First, corticosterone administration decreases 
cell proliferation, and secondly adrenalectomy increases SGZ neurogenesis (Zhao et al., 
2008; Mirescu and Gould, 2006). In contrast to stress, antidepressant administration is 
able to increase cell proliferation in the SGZ (Warner-Schmidt and Duman, 2006; Duman, 
2004). Furthermore, antidepressants are able to reverse the stress-mediated decrease in 
cell proliferation (Warner-Schmidt and Duman, 2006). However the most interesting 
aspect is that the time course of antidepressant-induced changes correspond with the 
time delay for mood-elevating effects in humans (Miller et al., 2007). When administering 
antidepressants 1 to 5 days, no effect on cell proliferation can be found. Nevertheless, 
after 7 to 14 days of antidepressant treatment, an increased rate of neuronal proliferation 
can be detected. Extending the antidepressant treatment up to 4 weeks, produces a 
significant increase in the cell survival rate (Malberg et al., 2000; de Foubert et al., 2004). 
To strengthen the hypothesis that neurogenesis is involved in antidepressant treatment 
outcome Santarelli and colleagues combined hippocampal irradiation with chronic 
fluoxetine treatment in mice to show that fluoxetine treatment was ineffective in 
hippocampal-irradiated mice (Santarelli et al., 2003). To date, cell proliferation studies 
have not been very conclusive in human analyses. However, imaging studies could reveal 
that a decrease in hippocampal volume as well as in other forebrain regions is present in 
a subset of depressed patients, and thus supports the theory of neurotrophic factors, 
neurogenesis and depression (Krishnan and Nestler, 2008).  
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Depression - influence of genetic and environmental factors 
Increasing evidence demonstrates that depression is highly influenced by genetic factors 
(Ising and Holsboer, 2006; Lesch, 2004), and is indeed a highly heritable disorder (up to 
38%) (Kendler et al., 2006). However, the search for specific relevant genes has been 
very disappointing so far (Nestler et al., 2002a). As depression is a very complex 
psychiatric disorder, it is hard to find one common gene responsible for the development 
of depression. It is more likely that many genes are involved in the development of the 
disorder (Burmeister, 1999). Alternatively, variations of genes may contribute to 
depression in every affected family. More and more studies demonstrate that single 
nucleotide polymorphisms (SNPs), genetic variations in one single gene, are capable of 
contributing to either a stress-resilient or stress-vulnerable phenotype, which consequently 
determines the chance of developing depressive disorders. Binder and colleagues could 
demonstrate that different SNP variations in the human corticotropin releasing hormone 
receptor type 1 (CRHR1) gene, a gene that is highly involved in HPA axis regulation, 
modulate individual stress susceptibility and lead to a higher risk of developing psychiatric 
disorders such as depression (Binder and Nemeroff, 2010; Ressler et al., 2010). However, 
individual vulnerability to depression is only partly driven by genetic factors. More and 
more studies demonstrate that environmental factors, namely stress or trauma, are also 
important key players in the development of depression (Nestler et al., 2002a). 
Depression is often referred to as a stress-related disorder. Evidence show that severe 
stress, including early trauma or chronic stress during adulthood, leads to an increased 
risk of developing depression (Nestler et al., 2002a; Heim and Nemeroff, 2001; Heim et 
al., 2008). In summary, these findings indicate that stress, per se, is not sufficient to cause 
depressive episodes. It rather seems likely that an interplay between genetic risk factors 
and environmental factors underlies the etiology of depression. 
Depression and the glutamate system 
Glutamate was first recognized as a neurotransmitter in the 1980s and it is now known as 
the major excitatory neurotransmitter in the central nervous system (CNS) (Orrego and 
Villanueva, 1993). Glutamate mediates fast excitatory transmission (Sanacora et al., 
2012), and the majority of brain neurons and synapses are glutaminergic in nature 
(Pessoa, 2008). Furthermore, glutamate synaptic transmission is a key player in 
mediating cognitive and emotional processes (Pessoa, 2008). In the 1990s, Trullas and 
Skolnick shed new light on the role of the glutamate system in depressive disorders. They 
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could demonstrate that a N-Methyl-D-aspartate (NMDA) receptor antagonist exert 
antidepressant-like effects (Trullas and Skolnick, 1990). Subsequent animal models 
revealed that different types of environmental stressors enhance glutamate release and 
transmission in limbic and cortical brain regions. These molecular changes result in 
structural alterations, e.g. dendritic remodeling and reduction of synapses, which in turn 
further alter synaptic transmission (Sanacora et al., 2012). To additionally strengthen the 
role of glutamate in depressive disorders, clinical studies provide evidence that glutamate 
transmission is abnormal in depressed patients (Sanacora et al., 2012). In fact, increased 
glutamate levels are found in the patients' plasma (Sanacora et al., 2012). Furthermore, 
studies have shown that antidepressant treatment is able to reduce the higher plasma 
glutamate levels in depressed patients (Altamura et al., 1995; Maes et al., 1998). Frey and 
colleagues could show in one study with a mixed set of patients (bipolar and unipolar 
depression) that glutamate levels were decreased in central spinal fluid (Frye et al., 2007). 
A postmortem brain tissue study of the frontal cortex of depressed patients stated an 
increase in glutamate levels (Hashimoto et al., 2007).  
Despite no clear unifying hypothesis of depression nor a comprehensive understanding of 
the underlying pathophysiological mechanisms of depression, effective treatment 
strategies are nonetheless already available. 
1.2 Antidepressant drugs 
During the mid-1950s two precursors of the main contemporary classes of 
antidepressants were discovered, iproniazid for MAOIs (Crane, 1956) and imipramine for 
tricyclic antidepressant drugs (TCAs) (Kuhn, 1957; Kuhn, 1989). This discovery 
subsequently led to the development of a large number of antidepressant compounds 
(Papakostas et al., 2007). Within the following decades, other classes of antidepressants, 
for example SSRIs and serotonin-norepinephrine reuptake inhibitor (SNRIs) were 
discovered and are nowadays commonly prescribed to treat depressive disorders 
(Papakostas et al., 2007). These antidepressants are in general effective but far from 
ideal, as their therapeutic effects presents a delayed onset, taking several weeks to exert 
their full clinical effects and are often accompanied by unwanted side-effects, such as 
body weight gain or fatigue (reviewed in (Flint and Kendler, 2014)). While many patients 
respond well to the currently available antidepressants, a significant number of patients 
neither show an adequate response to the treatment nor complete symptom relief, and 
often the patients relapse (Trivedi et al., 2006). In 2007, the Sequenced Treatment 
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Alternatives to Relieve Depression study (STAR*D) revealed that only one-third of 
patients on citalopram monotherapy remitted and the remaining two-thirds of patients 
failed to remit. In follow-up studies, other antidepressant monotherapies were prescribed 
to these patients (Trivedi et al., 2006). Based on this study and similar studies, it became 
clear, that treatment strategies are largely based on a trial and error principle (Fabbri et 
al., 2013) and that the longer the patients are treated, the less chance they have to remit 
(Trivedi et al., 2006). To-date, commonly prescribed antidepressants are mainly acting on 
monoamine transmission. Their main aim is to increase the concentration of monoamines 
on the one hand, by blocking reuptake or inhibiting monoaminergic neurotransmitter 
metabolism, or on the other hand, by blocking receptors downstream of monoaminergic 
signal transduction (Delgado, 2004). For example, SSRIs, SNRIs, norepinephrine 
reuptake inhibitors (NERIs) as well as norepinephrine and dopamine reuptake inhibitors 
(NDRIs) all fall within this category (Wong and Licinio, 2004; Yadid et al., 2000). 
Collectively, these antidepressant drugs are not completely selective for a single 
neurotransmitter and thereby potentially increase the side-effects (Lucki and O'Leary, 
2004). Regardless, SSRIs are still used for first-line antidepressant therapy (Nemeroff, 
2007). MAOIs as well as TCAs are used for second-line antidepressant therapy. TCAs 
mainly block the NE transporter and some also block the 5-HT transporter, which 
ultimately lead to higher levels of 5-HT and NE in the synaptic cleft, features, which 
underlie their antidepressant effects. MOAI can block an enzyme called monoamine 
oxidase (MAO), which degrades 5-HT and NE in the synaptic cleft and the presynaptic 
cell. Blocking the MAO leads to a lower degradation of the monoamines and is thus 
leading to higher concentrations of the neurotransmitters (Bortolato et al., 2008) (Figure 
1). 
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Figure 1: Work mechanisms of different antidepressant classes. The main aim of SSRIs is to increase the 
concentration of 5-HT (indicated in purple) by blocking the presynaptic 5-HT receptors (indicated in yellow) and 
thus blocking the reuptake of the neurotransmitters. 5-HT is longer available in the synaptic cleft and therefore 
exert its antidepressant effect. MAOIs can block an enzyme called MAO, which degrades 5-HT and NE in the 
synaptic cleft and the presynaptic cell. While blocking the MAO the degradation of the monoamines is prevented 
and thus leading to higher concentrations of the neurotransmitters (in this figure only 5-HT is represented as a 
neurotransmitter). TCAs mainly block the NE transporter and some also the 5-HT transporter, which is then leading 
to higher levels of 5-HT and NE in the synaptic cleft, both features that can lead to antidepressant effects. 
During the past years, advances in antidepressant treatment approaches were made 
when old antidepressants were "made-over" to novel classes of antidepressants, 
presenting improved treatment efficacy. For example, desvenlaflaxine, an active 
metabolite of venlaflaxine, was "made-over" into its own antidepressant. Desvenlaflaxine 
is less metabolized by cytochrome P450 2D6 (CYP2D6) compared to venlaflaxine and 
thereby demonstrates more stable plasma levels (Beyer and Stahl, 2010). The next 
generation of antidepressants are targeting novel structures, namely receptors, and range 
from low-molecular-weight compounds that are acting on the HPA axis (like R121919, a 
CRHR1 antagonists) to neurokinin receptor antagonists (Beyer and Stahl, 2010). For 
instance, CRHR1 antagonist (R121919) treatment could significantly reduce depression 
and anxiety scores in depressed patients (Zobel et al., 2000). Although the exploration 
trials of CRHR1 antagonists were very promising, more recently in follow-up studies, 
these drugs have not been successful (reviewed in (Holsboer, 2014)). 
Despite advances in novel antidepressant drug design, 40% of the patients do not present 
an adequate response to the first medication prescribed. Even more concerning, 30% of 
all patients with MDD do not respond to any intervention (Baghai et al., 2006). For these 
patients, it is typical to alternate between different classes of antidepressants, different 
concentrations and to combine different antidepressant drugs. Another novel approach for 
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treatment-resistant patients is the use of ketamine, a NMDA receptor antagonist. Clinical 
studies have demonstrated that, an acute injection of ketamine has rapid antidepressant 
effects without the unpleasant time-delay. Nevertheless, ketamine produces strong side 
effects and is therefore not suitable as a standard antidepressant therapy (Li et al., 2010). 
Electroconvulsive seizure therapy (ECT) is another therapeutic application that is used for 
treatment-resistant patients, in which generalized epileptic seizures are provoked by 
electrical stimulation of the brain (Frey et al., 2001).  
There are many possibilities to treat depression, however the clinical response to the 
treatment is not always satisfying. 
1.3 Depression and the hippocampus 
Neuroimaging technologies as well as neuropathological and lesion studies enabled in 
vivo characterization of anatomical and physiological correlates of mood disorders 
(Drevets, 2000; Czéh et al., 2001). These results as well as post-mortem studies shed 
new light on brain regions that are of major interest in mood disorders. It has been shown 
that brain regions involved in the regulation of mood and emotion, reward processing, 
attention, motivation, stress response as well as social cognition are altered in depressed 
patients (Phillips et al., 2003). The limbic-cortical-striatal-pallidal-thalamic circuit is formed 
by the connection between the orbital and medial prefrontal cortex, amygdala, 
hippocampus (HC), ventromedial striatum, mediodorsal and midline thalamic nuclei as 
well as the ventral pallidum (Öngür et al., 2003). Although various brain regions are 
important for a comprehensive understanding of depressive disorders, the hippocampal 
formation is one of the most studied brain regions in depressed patients (Videbech and 
Ravnkilde, 2004). It is involved in learning and memory (Fanselow, 2000), and is one of 
the few brain regions where adult neurogenesis occurs (Braun and Jessberger, 2014).  
The HC is a bilaminar grey-matter structure, which receives input from the amygdala, the 
claustrum, the septal complex and the supramammillary area, the hypothalamus, the 
thalamus and the brain stem. In turn, it projects to the septal nuclei, the thalamus, the 
mamillary, striatum as well as the amygdaloid complexes among others (Rosene and Van 
Hoesen, 1977). The laminae that form the HC complex consist of the DG and the cornu 
ammonis, which can be divided further into three regions, cornu ammonis region 1-3 (CA1 
- CA3), based on their pyramidal neuronal morphology and sensitivity to anoxia (Freund 
and Buzsaki, 1996; Lucas and Strangeways, 1963). The DG receives the principle 
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afferent input from the entorhinal cortex (ec) and then transmits the signal to the CA3 
neurons via the mossy fibers. The CA1 subregion represents the last station of the 
intrahippocampal trisynaptic loop and is mainly targeted via the pyramidal cells of the 
CA3, the Schaffer collaterals (Sc). The principle hippocampal output is formed by the CA1 
pathway via the subiculum, which projects to the ec formation, among others (Freund and 
Buzsaki, 1996).  
Extensive preclinical as well as clinical research have shown that the mnemonic and 
neuroplasticity function of the hippocampus is highly sensitive to stress, specifically 
elevated cortisol/corticosterone levels, which are often altered in depressed patients 
(Videbech and Ravnkilde, 2004; Checkley, 1996). Various studies have demonstrated that 
both physiological and psychosocial stress lead to adaptive changes in the hippocampus, 
e.g. reduction of neurogenesis in the DG. Indeed, the adult mammalian brain contains 
substantial numbers of neurogenic neural stem/progenitor cells (NSPCs) that retain the 
ability to generate new neurons throughout life, which is also known as adult 
neurogenesis (reviewed in (Braun and Jessberger, 2014)). However, adult neurogenesis 
is limited to two brain areas, namely the SGZ of the hippocampal DG and the SVZ lining 
the lateral ventricles (Braun and Jessberger, 2014). NSPCs reside in the SGZ of the adult 
DG and give rise to granular cell neurons via multiple steps. NSPCs, known as type 1 
cells, extend a radial process through the granular cell layer into the molecular layer and 
can then be activated to generate proliferating type 2 non-radial NSPCs. These type 2 
cells give rise to neuroblasts, which begin to branch out upon neuronal differentiation. 
Immature neurons migrate into the granular cell layer and over a 3-week period, newborn 
granule cell neurons form large dendritic arbor into the molecular layer as well as into the 
hilus, which then targets cells in the hilus and CA3 region (reviewed in (Braun and 
Jessberger, 2014)) (Figure 2). After migrating into the dentate granular layer the neurons 
become dentate granular cells and are thus integrated into existing circuits and begin to 
receive functional input (Zhao et al., 2008).  
The reduction in neurogenesis has been hypothesized to be linked to depressive episodes 
and has been shown to be restored following antidepressant treatment (see chapter 1). In 
line with this theory, clinical studies have shown a significant reduction in hippocampal 
volume in depressed patients compared to healthy controls (Krishnan and Nestler, 2008). 
Additionally, studies have demonstrated that antidepressants increase neurogenesis 
whereas chronic stress leads to a reduction in the neurogenesis rate. In terms of the 
delayed onset of antidepressant treatment response, it is very likely that alterations in 
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gene and protein expression could be the reason for the therapeutic effect. For instance, 
multiple studies have demonstrated that hippocampal neurogenesis-related genes, 
namely brain-derived neurotrophic factor (BDNF), play an important role in depression 
and antidepressant treatment (Duman and Voleti, 2012). It was shown that stress reduces 
BDNF synthesis, whereas antidepressants increase BDNF synthesis and signaling in the 
prefrontal cortex and HC (reviewed in (Zhao et al., 2008)). 
 
Figure 2: Signaling pathway and neurogenesis in the adult hippocampus in the mouse. The DG receives input from 
the ec and then pass on the signal to the CA3 neurons via the mossy fibers (mf). The pyramidal cells of the CA3 
target mainly the CA1. The principle hippocampal output is formed by the CA1 pathway. Adult neurogenesis occurs 
in the SGZ of the HC, where NSPCs reside. Type 1 cells, extent a radial process through the granular cell layer into 
the molecular layer and can then be activated to generate proliferating type 2 non-radial NSPCs. The type 2 cells 
give rise to immature neurons, which begin to branch out. Immature neurons migrate into the granular cell layer 
and newborn granule cell neurons form large dendritic arbor, the so called mature granule cells. 
1.4 Gene expression profiling in depression 
Gene expression profiling is a very propitious technique, and has successfully identified 
promising genes, such as SLC6A15 (Kohli et al., 2011). Within the past years, unbiased 
approaches, including microarray analysis or next-generation sequencing, have become 
attractive techniques to detect novel candidates and pathways, which underlie 
antidepressant treatment outcome (Ising et al., 2009; Tansey et al., 2013). 
Genetic factors strongly contribute to the development of many mental disorders. More 
and more studies have already shown that variations in specific alleles in combination with 
environmental factors affect individual susceptibility to develop mental disorders. For 
instance, Bradley and colleagues found a significant gene x environment interaction in 
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various SNPs in the CRHR1, a gene involved in the HPA axis. They demonstrated that 
specific CRHR1 polymorphisms were able to moderate the effect of childhood abuse on 
the risk of adult depressive symptoms (Bradley et al., 2008). Within the last years, 
genome-wide association studies (GWAS) gained more and more importance as their 
methodical properties as well as their statistical power to detect gene variations became 
more sensitive (Bush and Moore, 2012; Stranger et al., 2011; van der Sijde et al., 2014). 
Such studies aim to detect genetic factors that contribute to complex diseases, which 
often results from a combination of multiple genetic as well as environmental risk factors 
(Freimer and Sabatti, 2007). GWAS studies are carried out in two stages: first the 
discovery phase and in a second step, the replication phase. The discovery phase is used 
to screen the whole genome. In the replication phase, a subset of SNPs are tested in an 
independent cohort (Flint and Kendler, 2014). In comparison to candidate-gene studies 
that use either resequencing or association studies of specific genes, one advantage of 
GWAS studies is that the approach is unbiased, aiming to identify novel targets that may 
contribute to the examined disorder (Hirschhorn and Daly, 2005). Recently, GWAS have 
been performed for many common disorders, and in some cases, genomic regions with a 
strong linkage to the disease were identified, such as in type 1 diabetes (Nisticò et al., 
1996). However, for many diseases, these association studies showed limited success. 
When it comes to depressive disorders, and especially antidepressant treatment outcome, 
a meta-analysis combining three genome-wide pharmacogenetic studies, the Genome-
Based Therapeutic Drugs for Depression (GENDEP) project, the Munich Antidepressant 
Response Signature (MARS) project, and the STAR*D study, was performed aiming to 
identify biomarkers predicting antidepressant response. As depressed patients show a 
large heterogeneity in regard to treatment outcome, it was suggested that genetic 
variations might contribute to this variability (GENDEP Investigators et al., 2013). 
However, they were not able to detect reliable predictors of antidepressant treatment 
outcome (GENDEP Investigators et al., 2013). The authors suggest that sub-cohorts 
should be analyzed in the future, as they were able to detect a variant associated within 
the SSRI treated patients with early SSRI response (after 2 weeks of treatment). 
However, they state that this finding would not survive further statistical correction in their 
analysis (GENDEP Investigators et al., 2013). This study once again demonstrates that 
the outcome of antidepressant treatment is a very complex and heterogenic phenomenon. 
Therefore, it might be worthwhile to assess individual treatment outcomes in future 
studies. 
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1.5 SRY-box containing gene 11 (Sox11) - a novel antidepressant-inducible 
gene 
One of the genes that was extensively studied in this thesis is SRY-box containing gene 
11 (Sox11). The male sex determination gene Sry (sex-determining region Y), was the 
first of the Sox gene family that was discovered in the 1990s (Kiefer, 2007). All Sox genes, 
including Sox11, are transcription factors, and have been identified throughout the animal 
kingdom (Guth and Wegner, 2008).  
Structure and function of SoxC genes 
Ten Sox gene families have been described so far, SoxA – SoxH, grouped according to 
their amino acid identity (within one group > 70%) (Guth and Wegner, 2008). All of them 
contain a DNA-binding high-mobility group (HMG) domain that encodes the DNA-binding 
domain of a protein (Guth and Wegner, 2008). During the past decades, the role of Sox 
genes was receiving more attention in developmental processes, such as embryogenesis, 
gastrulation and stem cells (Guth and Wegner, 2008). Sox4, Sox11 and Sox12 are 
members of the SoxC family. SoxC genes are expressed in committed, postmitotic 
neuroblasts, which suggests that they are involved in the latter steps of neuronal 
development (Bergsland et al., 2006). Studies have shown that the SoxC group is mainly 
expressed in developing neurons, oligodendrocytes and astrocytes in the human brain 
(Bergsland et al., 2006; Jay et al., 1995). Furthermore, previous studies have shown that 
overexpression of SoxC activates panneuronal markers, namely tubulin, beta 3 class III 
(Tubb3) and microtubule-associated protein 2 (Map2) (Bergsland et al., 2006). Sox11 is 
expressed in the developing mouse nervous system (Bergsland et al., 2006), however is 
absent in many adult tissues (Xu and Li, 2010). Haslinger and colleagues revealed that 
within the adult mouse brain, Sox11 is mainly expressed in the DG of the HC and in the 
subventricular zone of the olfactory bulb. Furthermore, they showed that Sox11 is stage-
specifically expressed in cells of adult neurogenic lineage, whereas the transcriptional 
targets of Sox11 adult neurogenesis are still unknown (Haslinger et al., 2009).  
Sox11 and its involvement in diseases 
Sox11 is expressed in virtually all aggressive mantel cell lymphomas and was recently 
recognized as a diagnostic and prognostic antigen (Zeng et al., 2012). Apart from its role 
as a diagnostic marker in cancer research, very little is known about the physiological 
roles of Sox11 in adult organisms. It has been shown that Sox11-deficient mice present 
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various craniofacial and skeletal malformations, asplenia and hypoplasia of the lung and 
stomach. Importantly, these Sox11 malformations are in line with the human malformation 
syndrome (Sock et al., 2004). To-date there is a paucity information describing the 
behavioral characteristics of Sox11 in adult mice. The association between neurogenesis 
and psychiatric disorders suggests that insufficient neuronal proliferation, differentiation 
and connectivity during brain development and/or insufficient adult neurogenesis may 
contribute to the risk of illness (Sha et al., 2012) and therefore Sox11 would be an 
interesting candidate to investigate. 
1.6 Animal model of depression 
Modeling a neuropsychiatric disorder, for example depression, in rodents is a challenge 
on account of the complexity and vastness variety of symptoms in depressed patients. 
Furthermore, the psychological aspect cannot be modeled in animals as psychological 
parameters cannot be interpreted in rodents. Willner and colleagues developed a number 
of criteria that should be fulfilled in a potential valid animal model of disease (Willner, 
1984). The first criterion is the aspect of face validity within an animal model. High face 
validity means that there is a high degree of uniformity between the disease symptoms in 
humans and rodents. For depression this would include e.g. anhedonia, increased 
anxiety, alteration in HPA axis activity or sleep disturbances (Müller and Holsboer, 2006). 
Another very important aspect of any potential animal model is its predictive validity. This 
is achieved when treatment approaches, which are successful in the clinical situation, 
exert the same effects in the animal model. Finally, the third criterion is construct validity. 
High construct validity implies that the etiological processes underlying the disease state 
is the same in the animal model as in humans (Chadman et al., 2009). An example of high 
construct validity includes modeling a persisting genetic variant is present in the human 
disease state, either by overexpression or knockdown of a known disease-causing genetic 
mutation (Nestler and Hyman, 2010).  
Modeling antidepressant treatment  
Animal models aiming to investigate the influence of antidepressant treatment are 
commonly used within preclinical psychiatric research. However, such model systems 
present some limitations in terms of predictive validity (Figure 3). 
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Is the dosage used in the animal model comparable to the clinical situation?  
Most animal studies are conducted with very high dosages of antidepressants (for 
instance paroxetine: 18mg/kg BW; fluoxetine: 18mg/kg BW (Holick et al., 2007)). In 
comparison to the human situation (paroxetine and fluoxetine are administered with a 
dosage of 20 - 40mg per day for an average person of 70kg (≙ 0.29mg/kg - 0.57mg/kg 
BW)), it can be concluded that most of the studies are potentially overdosing the animals. 
How is the antidepressant drug applied? 
Many animal studies administer the antidepressant drugs via the drinking water (Wagner 
et al., 2012; Scharf et al., 2013), gavaging (Ganea et al., 2012; Sillaber et al., 2008; 
Webhofer et al., 2011) or via i.p. injections (Steru et al., 1985; de Montigny and 
Aghajanian, 1978). However, in the clinical situation we can see that most of the patients 
are treated with tablets. 
How long should a drug be administered to provoke a robust effect? 
In the human situation we can see that the majority of patients start responding to the 
antidepressant treatment after at least 4 - 6 weeks of treatment. However, in preclinical 
studies, the longest treatment period is 28d, with most studies employing even shorter 
treatment periods (Ganea et al., 2012; Fava et al., 2000; Sillaber et al., 2008; Vaugeois et 
al., 1997). Furthermore, several studies draw conclusions following an acute 
antidepressant exposure, whereas this acute antidepressant effect is not effective in the 
clinical practice. Collectively, it is evident that a large gap still exists between preclinical 
research and the actual clinical setting, and therefore the translational value of animal 
models for depression could be improved. 
Therefore, it would be desirable to mimic the clinical situation as closely as possible to get 
a better translational approach. 
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Figure 3: Illustration of the current clinical and preclinical situation of antidepressant response. There are many 
limitations at the moment when it comes to find the best treatment strategy for each patient. One reason for that is 
the lack of innovative pharmacological approaches, as most of the antidepressants used at the moment are based 
on the findings from the 1950s. These antidepressants are in general effective, although many patients do not 
present an adequate response to the treatment. Additionally, there is a lack of biomarkers that predict 
antidepressant response in humans. There is also a deficit of appropriate animal models that are mimicking the 
clinical situation as closely as possible. A first step towards better treatment strategies and biomarkers for 
antidepressant response might be the detection of novel targets by using an unbiased approach in a novel animal 
experimental approach. 
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1.7 Aim of the thesis 
The overarching aim of this thesis is to gain a insight into the neurobiology underlying 
individual treatment response in MDD. We directed our research towards addressing two 
major problems that currently impede advances in antidepressant drug development 
employing a translational strategy, namely, we sought to address:  
1. Identification of early biomarkers would promote evidence-based selection of 
antidepressant treatment options, rather than the trial and error approach currently used. 
As some patients already present a positive treatment effect after 14d of antidepressant 
treatment, we further aimed to identify novel candidate genes, biomarkers and pathways 
determining an early antidepressant response.  
2. The lack of conceptually novel antidepressant compounds. To further proceed in this 
field we aimed to establish a novel experimental approach that models antidepressant 
responsiveness in mice, and to subsequently implement this approach in order to identify 
novel targets mediating individual antidepressant response. To gain a better 
understanding of individual antidepressant response and the basis for the heterogeneity in 
antidepressant treatment outcome, we aimed to mimic the clinical situation as closely as 
possible.  
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2 Materials and Methods 
2.1 Animals 
The experiments were carried out with male DBA/2J mice obtained from Charles River 
(Charles River Laboratories, France). Animals were single housed in polycarbonate cages 
(21 x 15 x 14cm) with standard bedding and nesting material, with a 12L:12D cycle (lights 
on at 7am) as well as constant temperature (23 ± 2°C) and humidity (55 ± 5%). Standard 
mouse chow (Altromin 1324, Altromin GmbH, Germany) and tap water were provided ad 
libitum. All experiments were carried out in the animal facility of the Max Planck Institute of 
Psychiatry in Munich, Germany, in accordance with the European Communities Council 
Directive 2010/63/EU. All efforts were made to minimize animal suffering during the 
experiments. The protocols were approved by the committee for the Care and Use of 
Laboratory animals of the Government of Upper Bavaria, Germany. 
2.2 Experimental design 
2.2.1 Validation of a novel approach to investigate antidepressant response in 
mice  
2.2.1.1 Paroxetine - Dosage 
Dosage: 1mg/kg BW 
The aim of this study was to identify the minimum effective paroxetine dosage for the 
DBA/2J strain. Therefore, 41 male DBA/2J mice were randomly assigned to either the 
vehicle (n=11) or paroxetine (n=30) experimental group. Upon arrival, animals were at the 
age of 7 - 9 weeks and housed singly. Pharmacological treatment started at the age of 9 - 
11 weeks. The animals were treated with 1mg/kg body weight (BW) paroxetine or vehicle 
for 28 days twice a day (for details see 262.3). After the treatment interval the animals 
were subjected to a Forced Swim Test (FST) and sacrificed directly afterwards (Figure 
4A). Trunk blood and whole brains of the animals were collected and stored until further 
processing (for details see 2.4). 
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Dosage: 5mg/kg BW 
To identify the minimum effective dosage, a second experiment was performed using a 
paroxetine concentration of 5mg/kg BW. Animals were at the age of 7 - 12 weeks at the 
arrival and housed singly from the beginning on. Paroxetine treatment started at the age 
of 9 - 14 weeks. The animals were treated with 5mg/kg BW paroxetine (n=100) or vehicle 
(n=58) for 28d twice a day (for details see 2.3). On treatment day 29, the animals were 
subjected to a FST and sacrificed directly after the FST (Figure 4B). Trunk blood and 
brains of the animals were collected and stored until further use (for details see 2.4). 
 
Figure 4: Experimental time course. (A) Animals were randomly divided in vehicle and paroxetine treatment groups. 
Animals were treated with either 1mg/kg BW paroxetine or vehicle for 28d twice a day. Last drug administration 
was given to the animals on day 29 in the morning (6am). 4h later the animals were subjected to a FST and killed 
directly after the FST. (B) Animals were randomly divided in vehicle and paroxetine treatment groups. They were 
treated with either 5mg/kg BW paroxetine or vehicle for 28d twice a day. Last drug administration was given to the 
animals on day 29 in the morning (6am). 4h later the animals were subjected to a FST and sacrificed directly after 
the FST 
 
2.2.1.2 Paroxetine - Acute treatment effects 
In a next step, we investigated the effects of an acute paroxetine treatment and therefore 
male DBA/2J mice were either treated with 5mg/kg BW paroxetine (n=30) or vehicle 
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(n=50). Animals were between 12 - 14 weeks old and treated on the day of the behavioral 
testing, with one acute dosage of 5mg/kg BW paroxetine, 4h before the behavioral test 
and then sacrificed directly after the FST (Figure 5). Trunk blood and brains of the animals 
were collected and stored until further processing (for details see 2.4). 
 
Figure 5: Overview of experimental time course. Animals were treated on the day of the behavioral testing with one 
acute administration paroxetine (5mg/kg BW). 4h later the animals were subjected to a FST and directly sacrificed 
after the test. 
2.2.1.3 Route of administration: Acute administration of mouse pellets versus 
intraperitoneal injection (i.p.) 
I.p. injection is a common used technique to administer pharmacological agents to mice. 
We investigated in this study whether the pharmacokinetic effects of the customized 
palatable mouse pellets is comparable to i.p. injections. Therefore, 10 male DBA/2J mice 
were i.p. injected once with 5mg/kg BW dosage of paroxetine. The mouse pellet control 
group (n=30) originated from the acute treatment experiment (see chapter 2.2.1.2). Trunk 
blood and whole brains were collected at sacrifice to measure paroxetine levels (for 
details see chapter 2.7.2). 
 
2.2.1.4 Pharmacokinetics of paroxetine  
In order to get a better understanding of the pharmacokinetic profile of paroxetine, 
especially with regard to the pharmacological half-life in the mouse, 20 male DBA/2J mice 
were treated with 5mg/kg BW paroxetine twice a day for 28d (animals were 9 - 10 weeks 
old at the beginning of the treatment) (for details see 2.3). After the treatment period 
animals were killed at different time points (1d (n=5), 3d (n=5), 7d (n=5) or 14d (n=5)) 
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(Figure 6). Trunk blood and whole brains were collected at sacrifice and stored until 
further use (for details see 2.4). 
 
Figure 6: Overview of the experimental time course. Animals were treated with 5mg/kg BW paroxetine twice a day 
for 28d. After the treatment period animals were killed at different time points after discontinue with the paroxetine 
treatment. Animals were sacrificed 1d (n=5), 3d (n=5), 7d (n=5) or 14d (n=5) after discontinue the paroxetine 
treatment.  
2.2.1.5 The Forced Swim Test as a readout parameter for antidepressant response 
This study was designed to assess whether the FST is a suitable behavioral test to 
investigate the variability of antidepressant treatment response in mice. Animals were 
tested before and after the antidepressant treatment in the FST. This repeated testing was 
used to investigate whether differences in treatment response of the animals could be due 
to preexisting inherent characteristics. Therefore, 60 male DBA/2J mice were subjected to 
the first FST at the age of 8 - 9 weeks. After one week of recovery, the animals were 
treated twice a day for 28d with either 5mg/kg BW paroxetine (n=40) or vehicle (n=20) (for 
details see 2.3). On the last day of treatment the animals were tested in the FST for the 
second time (Figure 7). Animals were killed directly after the FST, trunk blood and whole 
brains were collected at sacrifice and stored until further processes (for details see 2.4). 
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Figure 7: Overview of the experimental time course. Male DBA/2J mice were tested at the age of 8 - 9 weeks in the 
FST for the first time. After one week of recovery, the animals were treated twice a day for 28d with either 5mg/kg 
BW paroxetine. On the last day of treatment the animals were tested in the FST. Animals were sacrificed directly 
after the FST. 
2.2.2 Detection of potential novel candidate genes after chronic paroxetine 
treatment 
In a next step, we were aiming to detect novel molecular targets mediating an individual 
antidepressant response after chronic paroxetine treatment within our novel experimental 
approach. Therefore, 158 male DBA/2J, aged 9 - 14 weeks, were treated with 5mg/kg BW 
paroxetine (n=100) or vehicle (n=58) for 28d twice a day (for details see 2.3). 
Subsequently, the mice were sacrificed directly after the FST (Figure 8). To investigate 
differences in antidepressant treatment response, the animals were divided into good, 
intermediate and poor treatment responders according to their performance in the FST 
(for details see chapter 2.5). Trunk blood and brains were collected and stored until further 
use (for details see 2.4).  
 
Figure 8: Overview of the experimental time course. Animals were randomly divided in vehicle and paroxetine 
treatment groups. Animals were treated with either 5mg/kg BW paroxetine or vehicle for 28d twice a day. Last drug 
administration was given to the animals on day 29 in the morning. Animals were subjected to a FST 4h later and 
sacrificed directly after the FST. 
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2.2.3 The role of Sox11 in antidepressant response and depression 
2.2.3.1 Characterization of Sox11 under different treatment conditions 
Based on the results obtained in 2.2.2 Sox11 was identified as a promising novel 
candidate gene. In order to investigate the influence of paroxetine treatment on Sox11 
expression, brains from the previous experiments (see chapter 2.2.1.3, 2.2.2 and 2.2.4) 
were processed for in situ hybridization (ISH) (2.7.8). 
2.2.3.2 The effects of reboxetine on Sox11 expression 
The aim of this study was to assess, whether the altered Sox11 messenger RNA (mRNA) 
expression is a SSRI-dependent effect or a general antidepressant effect. A total of 25 
male DBA/2J mice were treated for 28d with either vehicle (n=10) or reboxetine (n=15), a 
norepinephrine reuptake inhibitor (for details see 2.3). At the end of the treatment period, 
the animals were subjected to the dark-light box (DaLi) and the FST. Animals were 
sacrificed directly after the FST (Figure 9). Trunk blood and whole brains were collected 
and stored until further use (for details see 2.4). 
 
Figure 9: Overview of the experimental time course. DBA/2J mice were treated for 28d with either vehicle (n=10) or 
reboxetine (n=15). To characterize the behavioral effects of Reboxetine more detailed, the DaLi was used in 
addition to the FST. Animals were sacrificed directly after the FST. 
2.2.3.2 Influence of Sox11 overexpression on antidepressant-like behavior 
To provide a better insight into a putative function of Sox11 on emotional behavior, region-
specific overexpression (OE) of Sox11 in the DG of the HC formation was achieved by 
using a recombinant adeno-associated virus (AAV) (Schmidt et al., 2011b) 
(methodological details can be found in chapter 2.8). AAV-Sox11OE (n=23) and AAV-
empty (n=20) mice were generated through stereotaxic injection of the virus and allowed 
  MATERIAL AND METHODS 
 
24 
to recover for 4 weeks from the surgery. This time interval ensured a sufficient transgene 
expression. As Sox11 was upregulated after 28d of paroxetine treatment the animals were 
tested another four weeks later (in total eight weeks after the surgery). This time frame 
was chosen to activate potential downstream pathways in the same way as the chronic 
antidepressant treatment. The behavioral testing battery included an open field test (OF), 
a FST, DaLi, novelty induced hypophagia (NIH) and a Y-Maze (Figure 10). Animals were 
sacrificed under basal conditions and perfused for immunohistochemical confirmation as 
well as ISH of Sox11 OE. Whole brains were collected and stored until further processing 
(for details see 2.4). 
 
Figure 10: Overview of the experimental time course. Animals were randomly distributed to either AAV9 Sox11 OE 
or the AAV9 empty groups. After the surgery, the animals were allowed to recover for 4 weeks from the surgery. An 
upregulation of Sox11 was found after 28d of paroxetine treatment. To ensure that potential pathways will be 
activated due to the viral OE the animals were tested another 4 weeks later. The behavioral testing battery included 
an OF, FST, DaLi, NIH and a Y-Maze. Animals were sacrificed under basal conditions. 
2.2.3.3 Sox11 OE and its influence on neurogenesis 
We next asked whether an overexpression of Sox11 would also affect neurogenesis, 
thereby mimicking this known cellular antidepressant effect (Warner-Schmidt and Duman, 
2006; Sahay and Hen, 2007). 23 male DBA/2J mice were injected with either an AAV9-
Sox11 OE or AAV9-empty. Viral injection was performed in 12 - 13 weeks old DBA/2J 
male mice. 1µl of either AAV9-Sox11OE (n=12) or AAV9-emtpy (n=11) was injected 
bilaterally in the dorsal hippocampal DG region (for details see 2.8). After that, the animals 
were allowed to recover for four weeks from the surgery, which ensured a sufficient stable 
transgene expression. 5-bromo-2-deoxyuridine (BrdU) (Sigma Aldrich, Germany) was 
solved in 0.9% sodium chloride. Animals were then injected on three consecutive days 
with a 100mg/kg pulse. 16 animals (Sox11OE n=8; Empty control n=8) were perfused 2h 
after the last BrdU injection. This time point was used to investigate the proliferation rate 
of new DG cells as a readout of the viral overexpression of the Sox11. To investigate the 
maturation status of the new-born neurons (8 weeks after the surgery) 7 animals 
(Sox11OE n=4; Empty control n=3) were perfused 28d after the last BrdU injection. 
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Animals were perfused under basal conditions and whole brains were collected until 
further processing (for details see 2.4). 
2.2.3.4 Sox11 knockdown in combination with paroxetine treatment and its 
influence on antidepressant-like behavior 
To examine the effects of a Sox11 knockdown (KD) in combination with a chronic 
paroxetine treatment, viral injection was performed on 12 - 13 weeks old DBA/2J mice as 
previously reported (Schmidt et al., 2011b). AAV1/2-Sox11KD (n=35) and AAV1/2 
scrambled (SCR) (n=34) mice were generated (for details see 2.8) and allowed to recover 
for 4 weeks from the surgery to ensure a sufficient transgene expression. Subsequently, 
the animals were randomly assigned to either a vehicle control or a paroxetine treated 
groups and treated for 28d with paroxetine or vehicle. The behavioral testing battery 
included an OF, DaLi, NIH and a FST (Figure 11). Animals were sacrificed under basal 
conditions and perfused for immunohistochemical confirmation as well as ISH to verify the 
Sox11 KD (for details see 2.7.8 and 2.7.9). 
 
Figure 11: Overview of the experimental time course. Animals were randomly distributed to either AAV1/2 Sox11 
KD or the AAV1/2 SCR groups. After the surgery, the animals were allowed to recover from the surgery for 4 weeks. 
Subsequently, the animals were either treated for 28d with paroxetine or vehicle. The behavioral testing battery 
included an OF, DaLi, NIH and a FST. Animals were sacrificed under basal conditions. 
2.2.4 Detection of potential novel candidates after subchronic paroxetine 
treatment in the brain and periphery 
In order to detect potential novel biomarkers mediating antidepressant response and to 
identify candidates modulating an early antidepressant response in particular, a shorter 
treatment period was used for this study. Therefore, 140 male DBA/2J mice were treated 
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with either 5mg/kg BW paroxetine (n=90) or vehicle (n=50) for 14d twice a day (for details 
see 2.3). At the beginning of the paroxetine treatment animals were at the age of 9 - 12 
weeks. Subsequently, the animals were subjected to a FST and sacrificed directly after 
that. The animals were divided into good, intermediate and poor treatment responder 
according to their performance in the FST (for details see chapter 2.5) (Figure 12). Trunk 
blood and brains were taken at sacrifice and stored until further use (for details see 2.4). 
 
Figure 12: Overview of the experimental time course. Animals were randomly divided in vehicle and paroxetine 
treatment groups. Animals were treated with either 5mg/kg BW paroxetine or vehicle for 14d twice a day. Last drug 
administration was given to the animals on day 15 in the morning (6am). 4h later the animals were subjected to the 
FST and directly killed after the testing. 
2.3 Antidepressant treatment 
Paroxetine, a commonly used SSRI was chosen for the antidepressant treatment, with the 
exception of the reboxetine experiment (chapter 2.2.3.2). It could be demonstrated 
previously that DBA/2J mice are responsive to oral antidepressant treatment under basal 
and stress-free conditions (Sillaber et al., 2008; Sugimoto et al., 2011; Ohl et al., 2003; 
Yilmazer-Hanke et al., 2003). If not stated differently, paroxetine (Paroxetine 
hydrochloride; Sigma-Aldrich, Germany) or vehicle was (voluntarily self-) administered via 
customized palatable mouse pellets (40mg PQPellets, Phenoquest AG, Martinsried, 
Germany) with different concentrations of paroxetine. The animals were treated with 
5mg/kg BW paroxetine or vehicle for 1, 14 or 28 days twice a day (8am and 6pm) with the 
exception of the dose finding experiment where the animals were treated with a 
concentration of 1mg/kg BW (see 2.2.1.1). Body weight was assessed twice a week and 
according to the animal's body weight, each mouse was assigned to different treatment 
categories to ensure the right dosage for each animal (Table 1). On the last day of 
treatment, the last dosage was administered at 6am, 4h prior the behavioral testing in 
order to avoid acute treatment effects. For chapter 2.2.3.2 Reboxetine was used for the 
antidepressant treatment. Animals were treated twice a day (8am and 6pm) with 2mg/kg 
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BW reboxetine or vehicle for 28 days. Administration procedure was performed in the 
same way as stated for the paroxetine treatments.  
Table 1: Paroxetine and reboxetine treatment categories according to the animal's body weight. Body weight was 
assessed twice a week. Animals were assigned to the respective treatment categories according to their body 
weight. 
 
The consumption of the palatable mouse pellets was monitored after every administration. 
Animals that did not consume the pellets were excluded from the analysis (on average 
10% of the animals). 
2.4 Sampling procedure 
Before sacrificing the animals, they were anesthetized with isoflurane (Abbott GmbH & 
Co. KG, Germany) and decapitated. Trunk blood was collected in 1.5ml EDTA-coated 
microcentrifuge tubes (Kabe Labortechnik, Germany) or PCR-clean 1.5ml tubes filled with 
966µl PAXgene™ solution (ribonucleic acid (RNA) stabilizer reagent) (for detailed 
information see chapters 2.2.4 and 2.7.3.1). All blood samples were immediately placed 
on ice and centrifuged at 8000rpm for 15min at 4°C. Plasma was transferred to clean 
1.5ml microcentrifuge tubes and stored at -20°C until further processing. If not stated 
differently, the animals were sacrificed directly after the FST in order to avoid potential 
alterations in gene expression levels. 
Whole brains were removed and if the left hippocampal formation was extracted (chapter 
2.2.2 and 2.2.4) it was done on ice. The rest of this hemisphere was used for the 
measurement of paroxetine brain tissue concentration. The other hemisphere was 
collected for ISH. Whole brains or dissected brain tissues were immediately snap-frozen 
in pre-cooled 2-methylbutane (Carl Roth GmbH, Germany) and stored at -80°C. For 
immunohistochemistry, animals were deeply anesthetized with isoflurane and slowly 
perfused intracardially with 0.9% saline followed by 4% paraformaldehyde. Brains were 
post-fixed overnight in 4% paraformaldehyde followed by 3 nights incubation in 20% 
sucrose solution at 4°C and then stored at –80°C. 
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2.5 Modeling antidepressant response in mice with the FST  
A large heterogeneity in antidepressant treatment outcome is known from the clinical 
situation. To-date, there are no common approaches to investigate individual 
antidepressant response in mice. Therefore, we raised the question whether the 
heterogeneity in antidepressant treatment outcome can in general be modeled in mice in 
general. We hypothesized that we can modulate this large heterogeneity within a large 
experimental group (Figure 13), and thus mimicking the clinical situation. According to the 
animals' performance in the FST, the animals were divided into good, intermediate and 
poor treatment responders. Animals with a high time floating (top 20%) were classified as 
poor treatment responders, whereas animals that showed a very low time floating (bottom 
20%) were characterized as good treatment responders. Animals that performed like the 
average of the paroxetine treated animals were defined as intermediate treatment 
responders. The animals that performed around the mean of the vehicle treated group 
were used as the non-treated control group. According to the literature, the treatment 
duration seems to play an important role in the clinical situation. Many patients show a 
delayed onset of antidepressant response and most of them do not start responding 
earlier than 3 - 4 weeks after the beginning of the treatment (Taylor et al., 2006). 
However, a minority of patients already show an antidepressant response after 2 weeks of 
antidepressant treatment (so-called "early responder") (Papakostas et al., 2006). These 
clinically relevant time points were considered in this mouse model approach, i.e. a 
chronic antidepressant treatment (28d) and a subchronic antidepressant treatment (14d), 
the latter representing an early antidepressant response. To further mimic the clinical 
situation, the animals were dosed with paroxetine via customized mouse pellets.  
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Figure 13: Illustration of the heterogeneity in the FST of mice. Illustration of the heterogeneity in the FST of mice 
after 4 weeks of antidepressant treatment. This figure illustrates our hypothesis stating that if a large number of 
animals is treated with an antidepressant, in this case paroxetine, the animals will respond differently in the FST. 
Although all of them were treated the same this would postulate that not all of the animals will respond equally to 
the treatment. 
2.6 Behavioral testing 
In this study, various behavioral tests were performed. Tests were accomplished in a 
separate room in which the mice were housed during the testing period. Animals were 
allowed to habituate to the testing room for at least 7 days prior the testing. Housing 
conditions were the same as described for standard housing (see 2.1). All tests were 
performed during the light phase, between 7am and 12am to avoid potential behavioral 
alterations due to circadian variation of corticosterone levels (Barriga et al., 2001). All 
tests were recorded and analyzed (either automatically or manually) with the automated 
video tracking system ANY-maze (ANY-maze 4.5; Stoelting Co., Wood Dale, USA). 
2.6.1 Open field test  
The OF is used to investigate general and basic locomotion of the experimental animal 
(Crawley, 1985). Furthermore, the OF can also be used to screen anxiety related behavior 
in mice. The OF consists of square, enclosed arena (50 x 50 x 50cm) made of gray 
polyvinyl chloride (PVC). For the analysis, the area was virtually divided into a center zone 
(20 x 20cm), which was illuminated with 20lux and an outer zone illuminated with 
approximately 16lux. Animals were placed in the lower left corner of the apparatus at the 
beginning of the testing. The total test duration was 15min. The OF arena was cleaned 
thoroughly with tap water and dried after each animal. The main readout parameters in 
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this test were the preference of the inner zone (analyzed via entries, time, distance) as 
well as total distance traveled. 
2.6.2 Dark-light box  
As the DaLi is based on the conflict of spontaneous explorative behavior in a novel 
environment and the natural aversion of mice to avoid highly illuminated areas, it is a 
common test to investigate anxiety-related behavior in mice (Hascoet et al., 2001). The 
apparatus consists of a small, secure and dark compartment (15 x 20 x 25cm, with 
dimmed light condition < 10lux) and a larger, aversive and brightly illuminated 
compartment (30 x 20 x 25cm, brightly lit with 600lux), which are connected by a 4cm long 
tunnel. Animals were placed in the lower left corner of the dark chamber at the beginning 
of a 10min testing period. The DaLi was cleaned thoroughly with tap water and dried after 
each animal. The main readout parameter in this test was the preference of the light 
compartment (analyzed via latency to enter, total entries, total time, total distance in the lit 
compartment). 
2.6.3 Novelty induced hypophagia 
As the NIH is based on the conflict of the desire of a highly palatable food and the natural 
aversion of mice to avoid highly illuminated areas, it is a common test to investigate 
anxiety-related behavior in mice (Dulawa and Hen, 2005). The apparatus consists of a 
highly illuminated (600 - 1000lux) empty polycarbonate cage (21 x 15 x 14cm) located on 
a white surface to increase the aversiveness. The test comprises three days of habituation 
and two testing days. During the habituation period, the 30% sweetened condensed milk 
was presented to the mice in their home cage for 30min. Consumption was monitored, 
animals that did not consume any condensed milk during the habituation period were 
excluded from the analysis (less than 1%). On the first testing day, the sweetened 
condensed milk was presented to the animals in their home cage for 30min. Latency to 
consume as well as the amount was recorded. Animals that did not consume any 
condensed milk or with a latency of at least 300s were excluded from the analysis (less 
than 1%). On the second day, the mice were placed in the aversive environment for 
30min, again with the highly palatable food. Latency to consume and the total 
consumption of the condensed milk was measured at the end of the testing period. 
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2.6.4 Y-Maze 
The Y-maze test is a common test to investigate hippocampus-dependent spatial memory 
(Dellu et al., 2000; Dellu et al., 1992). The apparatus consisted of three arms (30 x 10 x 
15cm), made of gray PVC, which were arranged in an angle of 120° between two arms. 
This Y-shaped apparatus consisted of three separate zones all connected by a center 
zone. The whole apparatus was evenly illuminated with 15lux to avoid preferences based 
on illumination levels. Each arm was marked differently by easily recognizable symbols 
(triangle, bar and plus-sign). The testing comprises two different trials. During the first trial, 
the acquisition phase, one arm was completely blocked by a gray PVC wall. The mouse 
was placed in the center zone and was allowed to explore the two accessible arms freely 
for 10 minutes before returning to the home cage. After an intertrial interval of 30min mice 
were re-introduced to the apparatus facing one of the already known arms. During this 
retrieval phase (5min), all three arms were accessible. An indicator for spatial memory 
performance was the percentage of time spent in the novel arm compared to the familiar 
arms. Significantly higher percentage than chance level (33.3%) was rated as successful 
spatial memory. 
2.6.5 The Forced Swim Test  
The FST is a common test to model behavioral despair and antidepressant-like behavior 
in rodents (Porsolt et al., 1977a; Porsolt et al., 1977b). It is still the most commonly used 
test paradigm for screening antidepressant action of compounds. A glass beaker (height 
24cm, diameter 13cm) was filled with 21 ± 1°C water up to a height of 15cm, that the 
animal is not able to touch the ground or escape the situation. The animals were gently 
placed in the glass beaker for 5 minutes testing period. After this period, the animals were 
removed, dried and placed back into their home cage. Parameters of interest were time 
swimming, time floating and time struggling. 
2.7 Molecular methods 
2.7.1 Radioimmunoassay 
Radioimmunoassay (RIA) was performed with a commercially available double antibody 
kit with a sensitivity of 6.25ng/ml (ImmunoChemTM Double AntibodyCorticosterone 125I 
RIA Kit, MP Biomedicals, USA) according to manufacturers' manual in order to analyze 
corticosterone concentrations in the plasma of the animals.  
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2.7.2 Paroxetine concentrations in the brain and plasma 
Paroxetine was extracted out of mouse blood or brain according to Uhr et al. (Uhr et al., 
2003). In short, to analyze paroxetine concentrations in the homogenized samples, the 
high-performance liquid chromatography (HPLC) analysis was used. A mobile phase 
gradient was used for the chromatographic analysis of paroxetine and its metabolites. The 
substances and its metabolites were determined by UV absorption or fluorescence at the 
described wavelength. The coefficient of variance was less than 15% for the different 
methods used. To avoid differences due to day-to-day variability, experimental procedure, 
extraction procedure and HPLC were carried out in alternating order (Uhr et al., 2003). 
Plasma and brain samples were calibrated by using spiked samples at different 
concentrations. The concentrations were in the measurement range to the respective 
substances. Quantification was performed by calculating the analyte: internal-standard 
peak-area ratio, and a regression model was fitted to the peak-area ratio of each 
compound to internal standard versus concentration (Uhr et al., 2003).  
2.7.3 RNA isolation 
2.7.3.1 Whole blood 
RNA isolation out of blood was performed with blood samples originating from the 
experiments described in chapter 2.2.4. Trunk blood was collected individually in 1.5ml 
tubes. The blood was further processed according to the PAXgene™ blood miRNA Kit. 
350µl of this freshly collected trunk blood was immediately transferred into 1.5ml tubes 
filled with 966µl PAXgene™ solution (RNA stabilizer reagent), gently inverted 10 times 
and then incubated at RT for 2 – 24 hours and stored at -20°C before RNA isolation 
(Krawiec et al., 2009). Volume ratio of RNA stabilizer reagent to blood samples was kept 
at 2.76 according to the manufacturer’s protocol. RNA was isolated according to Krawiec 
and colleagues (Krawiec et al., 2009). Shortly, frozen samples were brought to room 
temperature for 45min, then inverted several times and then centrifuged at 5000 x g for 
10min at 22°C. The supernatant were aspirated and the pellet was resuspended in 0.5ml 
of RNase-free water by vortexing until the pellets were visibly dissolved. All following 
steps were conducted according to the manufacturers’ manual with the exception that 
proteinase K digestion at 55°C was performed for 60min at 700rpm/min on an Eppendorf 
shaker. The remaining trunk blood of each animal was collected in labeled 1.5ml EDTA-
coated microcentrifuge tubes (Kabe Labortechnik, Germany).  
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2.7.3.2 Whole blood RNA globin reduction 
Blood consists of a heterogeneous cell population of erythrocytes, granulocytes, and other 
peripheral mononuclear cells (PBMC) (Rainen et al., 2002). Due to this heterogeneity it is 
difficult to detect differences in gene expression levels. Blood itself contains a high 
amount of globin mRNA transcripts, which might mask differences in other mRNA 
transcripts. Therefore, we used the Ambion® GLOBINclear™-Mouse/Rat Kit after the 
RNA isolation. Globin reduction was performed according to the manufactures manual. 
Input RNA was quantified before the Globin reduction with a Nanodrop. This globin 
reduced RNA was then further processed, amplified and then used for microarray 
experiments. 
Globin-depleted total RNA was quantified with a Nanophotometer (Nanodrop 2000, Fisher 
Scientific) and quantified and quality-controlled by capillary gel electrophoresis (2100 
Bionanalyzer, Agilent; RNA 6000 nano Assay). The obtained RNA integrity numbers (RIN) 
were greater than 7.5 in all total RNA samples derived from blood before globin depletion 
and dropped slightly after globin depletion (RIN > 6.3 for all samples that were further 
analyzed). 
2.7.3.3 Hippocampus 
RNA isolation out of the left HC was performed with samples originated from the 
experiments described in chapter 2.2.2 and 2.2.4. Hippocampal RNA was isolated using 
the TRIZOL reagent (Invitrogen) as described previously (Schmidt et al., 2010), except 
that the tissue was homogenized with syringes. For RNA quality and integrity analysis 
Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Waldbronn, Germany) as well as 
RNA Nano LabChips (Agilent Technologies, Inc., Waldbronn, Germany) were used. The 
measurements were performed according to manufacturers' protocol. Among other 
parameters, the 28S:18S ratio of the RNA bands, was analyzed and should lie about 2.0. 
The Agilent software is able to calculate the RIN of the sample by using the 28S:18S ratio 
and other features. Samples with a RIN < 7.0 were excluded from the analysis (less than 
5%). 
2.7.4 RNA amplification 
Globin-depleted RNA as well as hippocampal RNA were labeled and linearly amplified to 
complementary RNA (cRNA) in a commercial form of the classical procedure by Eberwine 
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(Van Gelder et al., 1990). 250ng of RNA was used as input for the Illumina® TotalPrep™-
96 RNA Amplification Kit (Life technologies) and sample processing was performed 
according to the manufacturers' protocol. RNA was again quantified and quality checked 
as performed with total RNA. All samples underwent photometric analysis (Epoch 
Spectrophotometer with Take3 Trio Micro-Volume Plate, BioTek Instruments GmbH) and 
a selected cross section of the samples has been additionally checked on the 
Bioanalyzer. 
2.7.5 cDNA transcription 
The VILOSuperScript Kit (Life Techologies) was used for the transcription of RNA to 
complementary DNA (cDNA) for the quantitative reverse transcription polymerase chain 
reaction (qRT-PCR). The transcription was performed according to the manufacturers' 
protocol. Thereafter, samples were loaded into a thermal cycler, using the protocol 
indicated in the manufacturers' manual. Transcribed cDNA was then stored at -80°C until 
further use. 
2.7.6 Microarray analysis 
For transcriptome analysis the MouseWG-6 v2.0 BeadChips (Illumina Inc.) were used, 
allowing the identification of about 45.281 gene-sequences (50mer oligonucleotides). The 
preparation of the samples for the microarray chips was done according the Illumina 
protocols. Chips were analyzed using the BEADARRAY package (www.bioconductor.org) 
with additional required packages. The animals for the microarray study were part of the 
cohort described in chapter 2.2.2 (poor responders n=13; intermediate responders n=8; 
good responders n=12; vehicle n=9) and 2.2.4 (poor responders n=12; intermediate 
responders n=8; good responders n=12; vehicle n=12) and selected according their 
behavioral performance in the FST and RNA quality. 
The animals selected for the blood microarray were the same animals as used for the 
brain microarray (for details see 2.2.4) except of the intermediate responder group, which 
was not included in this analysis. 
2.7.7 Quantitative reverse transcription PCR 
In order to investigate differences in gene expression levels, quantitative reverse 
transcription PCR (qRT-PCR) was used. 1µl of each cDNA was analyzed with the 
Nanodrop, for quality control. cDNA originated from the same samples as the microarray 
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samples (for details see chapter 2.2.2 and 2.2.4) and were analyzed by qRT-PCR, using 
the QuantiFast SYBR Green PCR Kit (Qiagen GmbH, Hilden, Germany) according to the 
manufacturers' instructions. Experiments were performed in duplicates with the Lightcycler 
2.0 instrument (Roche Diagnostics, Mannheim, Germany) under the following PCR 
conditions: initial denaturation at 95°C for 10min, followed by 40 cycles of denaturation 
(95°C for 10sec) and a combined annealing and extension phase (60°C for 30sec). At the 
end of every run, a melting curve (50 – 95°C with 0.1°C s–1) was generated to ensure the 
quality of the PCR product. Experimental analyses were performed on the crossing points, 
which were calculated by the LightCycler Software 4.0 (Roche Diagnostics GmbH) using 
the absolute quantification fit point method. Noise band and threshold were set to the 
same level in all compared runs. Relative gene expression was determined by the 2−ΔΔCT 
method (Livak and Schmittgen, 2001) using the real PCR efficiency calculated from an 
external standard curve. Crossing points were normalized to the housekeeping gene Hprt. 
All measurements were normalized to vehicle (vehicle being 1) or poor treatment 
responders (poor treatment responders being 1) to provide relative expression levels. 
Primers were designed with the free-online tool Primer3Plus (Rozen and Skaletsky, 
2000). Detailed information for the primer used in this experiment can be found in Table 2 
and Table 3. 
  MATERIAL AND METHODS 
 
36 
Table 2: Primers used for quantitative reverse transcriptase PCR in hippocampal brain tissue. The left column 
indicates the most common used symbols in public databases. The middle and right columns indicate the 
sequences of the forward and reversed primers used in the validation experiment. They are represented here in 5' 
to 3' direction. 
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Table 3: Primers used for quantitative reverse transcriptase PCR in peripheral blood. The left column indicates the 
common used symbols in public databases. The middle and right columns indicate the sequences of the forward 
and reversed primers used in the validation experiment. They are represented here in 5' to 3' direction. 
 
2.7.8 In situ hybridization  
Frozen brains were sectioned at -20°C in a cryostat microtome at 18μm, thaw mounted on 
Super Frost Plus slides, dried and stored at -80°C. ISH using a 35S UTP labeled 
ribonucleotide probe for Sox11 (Forward primer: TCATGTTCGACCTGAGCTTG; Reverse 
primer: CACGATAAAGGACGGGAAGA; transcript size: 480 nucleotides) was performed 
as described previously (Schmidt et al., 2007). The slides were exposed to Kodak Biomax 
MR films (Eastman Kodak Co., Rochester, NY) and developed following 6d of exposure. 
Autoradiographs were digitized, and expression was determined by optical densitometry 
utilizing the freely available NIH ImageJ software. The mean of two measurements of two 
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different brain slices were calculated for each animal. The data was analyzed blindly, 
always subtracting the background signal of a nearby structure not expressing the gene of 
interest from the measurements. 
2.7.9 Immunohistochemistry and immunostaining 
Immunohistochemistry was used to quantify AAV-Sox11-induced protein expression. 
Serial coronal sections were cut at 25μm thickness at -20°C. Double-labeling 
immunofluorescence (Goat-anti-Sox11, 1:250, Santa Cruz, C-20; donkey-anti-goat 555, 
1:500, Alexa) was performed on free-floating sections (Sox11 OE n=8; Empty n=8) as 
described previously (Wang et al., 2013).  
BrdU and NeuN immunostaining was performed by Lie and his colleagues according to a 
previously published paper (Garrett et al., 2012). 
2.8 Stereotactic surgery 
To provide a better insight into a putative function of Sox11 in the brain, a region-specific 
overexpression and knockdown of Sox11 in the dorsal DG was achieved by using a 
recombinant AAV. 
2.8.1 Viral vector construct 
Viral overexpression of Sox11 was performed as described previously (Schmidt et al., 
2011b). A custom-made AAV9 vector (preparation according to previously published 
protocols (Foust et al., 2009; Mu et al., 2012a)) was used for this experiment (kindly 
provided by Chichung D. Lie from the University of Erlangen). For the viral knockdown of 
Sox11 an AAV1/2 vector was used (GeneDetect, New Zealand) containing the U6--Mouse 
Sox11 2x shRNA--terminator-CAG-EGFP-WPRE-BGH-polyA. The same vector was used 
for the control groups (SCR group), expressing only EGFP (U6--GeneDetect SCR 2x 
shRNA--terminator-CAG-EGFP-WPRE-BGH-polyA). 
2.8.2 Stereotactic intra-hippocampal injection 
Viral injection was performed according to Monory (Monory et al., 2006). In short, animals 
were deeply anesthetized with isoflurane (Curamed Pharma GmbH, Germany) and 
inserted into a stereotactic frame (TSE system GmbH, Germany). The skull was exposed 
and holes were drilled bilaterally at the injection sites, targeting the dorsal DG of the HC 
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(1.6mm posterior to bregma, 1.3mm lateral from midline, and 1.7mm below the surface of 
the skull). 1µl of the corresponding virus (Titers: > 1.2 × 1012 genomic particles/ml) was 
injected at 0.06μl/min by glass capillaries with tip resistance of 2 - 4MΩ. To avoid reflux, 
class capillaries were removed five minutes after the injection. The wound was sutured 
and treated with iodine. The mice were treated after the surgery for 5 days with 
Metacam® via drinking water. 
2.9 Statistics 
The data presented are shown as means + standard error of the mean, analyzed by the 
commercially available software SPSS 16.0. For comparing two independent groups (e.g. 
vehicle versus paroxetine), data were analyzed with two-tailed, independent samples 
Student's t-test. For the calculation of the mortality rate, the Fisher's exact test was used. 
Therefore, the data was uploaded to the free online calculator tool 
(www.langsrud.com/fisher.htm) and significant level was calculated by generating a 2 x 2 
contingency table. For variables with more than two groups, one-way ANOVA was 
performed followed by Bonferroni post-hoc testing. For more complex datasets (2 x 2 
design; e.g. chapter 2.2.3.4), 2-way ANOVA was used. Correlations were analyzed with a 
two-tailed, bivariate Pearson's correlation analysis. As nominal level of significance p < 
0.05 was accepted, a trend was recognized at p ≤ 0.1. Values outside the 95% confidence 
interval (CI) were defined as statistical outliers and excluded from the analyses.  
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3 Results 
3.1 Antidepressant response in mice - methodological considerations 
In order to validate the novel experimental approach, which aimed to investigate 
antidepressant response in mice, some important questions were raised in the beginning. 
3.1.1 Dosing 
To identify the minimum effective dosage for the DBA/2J mouse strain, male mice were 
randomly distributed to either the vehicle or paroxetine experimental group and were 
treated with different concentrations of paroxetine. 
Trial 1: 1mg/kg BW (twice a day) 
To investigate, whether a very low dose of paroxetine is sufficient to evoke an adequate 
behavioral and pharmacological effect, animals were treated with 1mg/kg BW paroxetine 
(n=30) or vehicle (n=11) for 28 days twice a day (8am and 6pm) and killed on day 29 
directly after the FST (Figure 14A).  
Clinical studies have reported alterations in body weight gain following antidepressant 
treatment (Pijl and Meinders, 1996; Vanina et al., 2002), and therefore we also 
investigated this parameter in our experiment. 28d of paroxetine treatment (1mg/kg BW) 
led to a significant increase in body weight gain in the paroxetine treated animals 
compared to the vehicle treated animals (T39 = -2.490, p < 0.05) (Figure 14B). To analyze 
the effects of a 1mg/kg chronic paroxetine administration on a neuroendocrine level, we 
examined corticosterone levels and did not detect any significant difference between 
vehicle and paroxetine treated animals (Figure 14C). This low paroxetine dosage seems 
to influence physiological parameters, like body weight gain, but was not able to evoke a 
treatment effect on a neuroendocrine level. 
As the FST is the main readout parameter to investigate antidepressant treatment 
response in this model, we analyzed the animals' performance in the FST after 28d of 
antidepressant treatment. Paroxetine treated animals showed a tendency in a lower time 
floating compared to vehicle treated animals (T39 = 1.979, p = 0.55) (Figure 14D), but 
neither time swimming nor time struggling was significantly different between the groups 
(Figure 14E).  
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Figure 14: Neuroendocrine, physiological and behavioral parameters from the dosing experiment (1mg/kg BW). (A) 
Experimental time course of the study. (B) 28d of 1mg/kg BW paroxetine treatment led to an increase in body 
weight gain in the paroxetine treated animals. (C) Corticosterone levels were not altered due to the treatment. (D) 
Paroxetine treatment led to a trend in reduced time floating in the treated animals compared to the control group. 
(E) Chronic treatment did not alter the time struggling in the paroxetine treated group. * significant correlation, p < 
0.05. 
To get a detailed picture of the pharmacological profile of the antidepressant drug in the 
mouse, paroxetine levels were measured in the brain and the plasma of the treated 
animals. The animals were split up by the median in two groups according to their 
performance in the FST. No significant difference was found in paroxetine plasma 
concentrations within the compared groups (Figure 15A). When investigating the brain 
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paroxetine levels, no significant difference was detected among the two different 
behavioral groups (Figure 15B). However, paroxetine brain and plasma concentrations 
were highly correlated (r = 0.869, p < 0.000) (Figure 15C).  
 
Figure 15: Pharmacological profile of 1mg/kg BW in the mouse brain and periphery. (A) Chronic paroxetine 
treatment did not change plasma paroxetine concentrations in the upper median group compared to the lower 
median group. (B) No effect was found in the brain paroxetine concentration among the groups. (C) Higher brain 
concentrations of paroxetine were accompanied by higher plasma paroxetine concentrations. * significant 
correlation, p < 0.05. 
To summarize, we can conclude that 1mg/kg BW was an insufficient dosage to evoke 
robust behavioral treatment effects in our experimental model. 
 
Trial 2: 5mg/kg BW (twice a day) 
As the lower paroxetine concentration did not evoke the intended behavioral phenotype, 
another paroxetine concentration was tested in male DBA/2J mice. This time, 158 mice 
were treated with 5mg/kg BW paroxetine (n=100) or vehicle (n=58) for 28d twice a day 
(8am and 6pm) and were killed on day 29 directly after the FST (Figure 16A). To 
investigate the effects of the higher paroxetine dosage on physiological parameters, the 
body weight was assessed in these animals. 28d of paroxetine treatment (5mg/kg BW) led 
to a significant increase in body weight gain in the paroxetine treated animals compared to 
the vehicle treated animals (T148.587 = -11.263, p < 0.000) (Figure 16B). The higher 
paroxetine dosage was also able to evoke a significant reduction in stress-induced 
circulating corticosterone levels. Paroxetine treated animals showed lower corticosterone 
levels compared to the vehicle treated control group (T143 = 2.129, p < 0.05) (Figure 16C).  
Regarding the behavioral readout of the higher paroxetine dosage, chronic treatment 
significantly reduced the time floating in the paroxetine treated animals compared to the 
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vehicle treated group (T143 = 9.986, p < 0.000) (Figure 16D). Additionally, paroxetine 
treated animals showed a significantly higher level of active behavior compared to the 
vehicle treated animals (Time swimming: T143 = -2.633, p < 0.01, vehicle: 105.59sec ± 
4.70; paroxetine: 119.71sec ± 3.70; Time struggling: T140.984 = -7.820, p < 0.000 (Figure 
16E)). 
 
Figure 16: Neuroendocrine, physiological and behavioral parameters from dosing experiment (5mg/kg BW). (A) 
Experimental time course of the study. (B) 28d of 5mg/kg BW paroxetine treatment led to a significant increase in 
body weight gain in the paroxetine treated animals. (C) Corticosterone levels were significantly reduced in the 
paroxetine treated animals. (D) Paroxetine treatment led to a significant decrease in time floating in the treated 
animals compared to the control group. (E) Chronic treatment significantly increased the time struggling in the 
paroxetine treated group. * significant correlation, p < 0.05. 
After 28d of antidepressant treatment, paroxetine levels were measured in the brain and 
the plasma of the paroxetine treated animals. No significant difference was found in 
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paroxetine plasma concentrations (Figure 17A) or paroxetine brain concentrations (Figure 
17B) between the different responder groups after 28d of paroxetine treatment. However, 
we could show again a correlation between paroxetine brain and plasma concentrations (r 
= 0.905, p < 0.000) (Figure 17C). 
 
Figure 17: Pharmacological profile of 5mg/kg BW in the mouse brain and periphery. (A) Chronic paroxetine 
treatment did not change plasma paroxetine concentrations between the behavioral groups. (B) No effect was 
found in the brain paroxetine concentration among the groups. (C) Higher brain concentrations of paroxetine were 
accompanied by higher plasma paroxetine concentrations. * significant correlation, p < 0.05. 
We could conclude from the dosing experiment that 5mg/kg BW is the minimum effective 
dosage that evoked a robust physiological, neuroendocrine as well as behavioral 
phenotype in the DBA/2J mouse strain.  
3.1.2 Acute antidepressant administration 
As acute antidepressant applications are widely used in animal studies, we were 
interested whether an acute paroxetine administration via the mouse pellets evokes the 
same behavioral effects as already found in the literature (Cryan et al., 2005; Slattery and 
Cryan, 2012). Therefore, 80 male DBA/2J mice were treated with 5mg/kg BW paroxetine 
(n=30) or vehicle (n=50) (Figure 18A). 
When investigating physiological parameters, we did not detect a significant difference in 
body weight gain between the groups. The same counted for neuroendocrine parameters. 
We did not find any difference in corticosterone concentrations after an acute 
antidepressant treatment (Figure 18B).  
However, an acute paroxetine administration was able to evoke a behavioral response in 
the FST. Paroxetine treated animals showed a reduction in time floating compared to the 
vehicle treated control animals (Figure 18C) (T75 = 3.590, p< 0.001) and increased active 
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behavior (time swimming T75 = -2.526, p < 0.05, vehicle: 112.05sec ± 4.74; paroxetine: 
133.48sec ± 7.61 and time struggling: T75 = -2.019, p < 0.05) (Time struggling is shown as 
a representative for active behavior Figure 18D). 
 
Figure 18: Neuroendocrine, physiological and behavioral parameters after acute paroxetine treatment (5mg/kg BW). 
(A) Experimental time course of the study. (B) Acute paroxetine treatment (5mg/kg BW) did not alter corticosterone 
levels. (C) Paroxetine treatment reduced the time floating in the FST in the treated animals compared to the control 
group. (D) Acute treatment also led to an alteration in time struggling in the paroxetine treated group. * significant 
difference from vehicle treated control group, p < 0.05. 
 
To further investigate the pharmacology of the antidepressant drug in the mouse, 
paroxetine levels were measured in the brain and the plasma. Treated animals were split 
up by the median in two groups according to their performance in the FST. For plasma 
paroxetine levels, no difference was found between the groups, although the upper 
median group showed a tendency to a higher paroxetine plasma concentrations (T23 = 
1.965, p = 0.062) (Figure 19A). A significant difference in paroxetine concentrations was 
detected in the brain. Animals subjected to the upper median group showed higher brain 
paroxetine levels (T23 = 2.167, p > 0.05) compared to the lower median group (Figure 
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19B). Nevertheless, we could again demonstrate that paroxetine brain and plasma 
concentrations were highly correlated (r = 0.861, p < 0.000) (Figure 19C).  
 
Figure 19: Pharmacological profile of an acute 5mg/kg BW in the mouse brain and periphery. (A) Acute paroxetine 
treatment did not change plasma paroxetine concentrations between the groups. (B) Animals subjected to the 
upper median group showed significantly higher brain paroxetine concentration compared to the lower median 
group. (C) Higher brain concentrations of paroxetine were accompanied by higher plasma paroxetine 
concentrations. * significant difference between lower and upper median, significant correlation, p < 0.05. 
3.1.3 Acute i.p. injection versus acute mouse pellet 
I.p. injection is one of the most common tools in preclinical science for pharmacological 
drug application. To ensure that the mouse pellet is a comparable tool to the commonly 
used i.p. injection, 10 male mice were injected once with 5mg/kg BW paroxetine. 30 male 
DBA/2J mice served as a control group (see detailed results in chapter 3.3). I.p. injected 
animals showed significantly higher plasma paroxetine levels (T33 = 2.863, p < 0.01) and 
brain paroxetine levels (T33 = 3.740, p < 0.01) compared to the animals treated with the 
mouse pellet (Figure 20A-B). We could again show that plasma and brain paroxetine 
concentrations are correlated (r = 0.883, p < 0.01) after an acute i.p. injection (Figure 
20C). These findings are in line with our previous findings from the mouse pellets. 
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Figure 20: Pharmacological profile of an acute 5mg/kg BW in the mouse brain and periphery. (A) Acute i.p. 
paroxetine treatment led to higher plasma paroxetine concentrations compared to the mouse pellet treated group. 
(B) Acute i.p. paroxetine treatment led to higher brain paroxetine concentrations compared to the mouse pellet 
treated group. (C) After acute i.p. injection of 5mg/kg BW higher brain concentrations of paroxetine were 
accompanied by higher plasma paroxetine concentrations. *significant difference between i.p. injected group and 
mouse pellet group, * significant correlation, p < 0.05. 
3.1.4 Half-life study 
After we had identified the minimum effective dosage for the DBA/2J mouse strain 
(5mg/kg BW), we were aiming to get a better understanding of the pharmacokinetics of 
paroxetine especially with regard to pharmacological half-life of paroxetine within the 
mouse organism. 20 male DBA/2J mice were treated chronically with 5mg/kg BW 
paroxetine twice a day and were killed 1d (n=5), 3d (n=5), 7d (n=5) or 14d (n=5) after 
discontinuation of the paroxetine treatment (Figure 21A). One day after discontinuation of 
the antidepressant, the animals showed a 50% reduction of the paroxetine levels 
compared to the measured values right after the FST. Paroxetine plasma are no longer 
detectable from day 3 on (Figure 21B). Paroxetine was detectable a little bit longer in the 
brain, although there was very little left after 3 days of discontinuation of the treatment 
(Figure 21C). 
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Figure 21: Pharmacological profile after discontinuation of 28d paroxetine treatment (5mg/kg BW) in the mouse 
brain and periphery. (A) Experimental time course. (B) Paroxetine plasma levels showed a 50% reduction of the 
paroxetine levels compared to the paroxetine levels data set right after the FST one day after withdrawal of the 
antidepressant. Already three days after discontinuation of the treatment, no more paroxetine could be detected in 
these animals. (C) Brain paroxetine levels showed a 50% reduction of the paroxetine levels compared to the 
paroxetine levels data set right after the FST one day after discontinuation of the antidepressant. Three days after 
discontinuation of the treatment a small amount of paroxetine could still be detected in these animals. 
3.1.5 The FST as a valid readout for antidepressant treatment outcome in mice 
In order to analyze whether the differences in individual antidepressant treatment 
response is due to pre-existing inherent behavioral characteristics, 60 animals were 
subjected to a FST and following one week of recovery treated for 28d with either 
paroxetine (n=40) or vehicle (n=20). After the treatment period the animals were screened 
in a second FST (Figure 22A). After the 28d treatment period, paroxetine treated animals 
showed a lower time floating (T47 = 4.695, p < 0.000) and higher time struggling compared 
to the vehicle treated animals (T47 = -2.026, p < 0.05) (Figure 22B-C). Furthermore, time 
swimming was also increased in the paroxetine treated animals compared to the vehicle 
treated control group (T47 = -2.328, p < 0.05, vehicle: 117.56 ± 11.54; paroxetine: 152.59 ± 
9.48). As the time floating is our main readout parameter in this experimental design, we 
correlated the time floating of the animals under basal conditions with the time floating 
after the paroxetine treatment. Our results did not show any significant correlation in the 
investigated parameters (r = 1.80, p = 0.340) (Figure 22D).  
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Figure 22: Behavioral profile of a repeated FST after 28d of paroxetine treatment (5mg/kg BW). (A) Experimental 
time course. (B) Time floating in the second FST following 28d of paroxetine treatment. Paroxetine treated animals 
showed significant lower time floating compared to the vehicle treated control group. (C) Time struggling in the 
second FST. Paroxetine treated animals showed significant higher time struggling compared to the vehicle treated 
control group. (D) When correlating the time floating in the FST before and after the paroxetine treatment, no 
correlation was found between the performance of the animals. * significant difference between vehicle treated 
control group and paroxetine treated group, p < 0.05. 
3.2 Genes and pathways modulated after chronic paroxetine treatment 
In a next step, we were interested in genes and pathways that are differently regulated in 
good and poor responders as well as between vehicle and paroxetine treated animals 
after a chronic antidepressant treatment. 
3.2.1 Microarray analysis 
158 mice were treated with 5mg/kg BW paroxetine (n=100) or vehicle (n=58) for 28d twice 
a day (8am and 6pm) and were killed on day 29 directly after the FST. For detailed 
information and results see chapter 3.1.1, as the here described animals were part of this 
cohort. As we were aiming to identify novel genes and pathways, mediating an individual 
antidepressant response, we investigated the individual behavior of the animals. After 
identifying good (n=12), poor (n=13) and intermediate (n=8) treatment responders as well 
as the vehicle treated control group (n=9) (for detailed information see 2.5) a whole 
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genome gene expression microarray was conducted with hippocampal brain tissue 
(Figure 23).  
 
Figure 23: Identification of different responder groups according to their performance in the FST. Animals indicated 
in the red squares are referred as good and poor treatment responder. Animals that showed a very high time 
floating represented the poor treatment responder, whereas animals that showed a very low time floating 
represented the good treatment responder. Animals indicated with the green dotted squares are representing 
internal control groups. The animals within the paroxetine treated group are representing the intermediate 
responder group and served as a treated control group. The animals within the vehicle treated group served as a 
vehicle treated control group. 
Analysis of the Illumina microarray chip revealed 36 regulated genes between vehicle 
treated animals and good responder at a false discovery controlled significant level of 
10% (q < 0.1). Duplicates were removed in a next step (n=2) as well as genes that were 
detected by the microarray but were not specific for the respected gene (n=4), resulting in 
30 differentially regulated genes. A detailed gene list containing all relevant parameters 
can be found in Table 4. 
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Table 4: Significantly regulated genes in the hippocampal DG region 28d after paroxetine treatment. Genes are 
ordered by their functional classes. Fold Change is normalized to vehicle treated animals. 
 
We did not detect any significant difference between good and poor treatment responders 
after correcting for multiple testing. 
3.2.2 Validation of potential candidates with qRT-PCR 
12 genes were selected for further investigation. The selection was based on the gene 
expression pattern (www.brain-map.org) as well as evidences from the literature that 
these genes are involved in pathophysiological processes, which have been linked to the 
neurobiology of psychiatric disorders, such as neurogenesis, receptor activity, immune 
system or intracellular signaling. In a next step, we performed qRT-PCR with the same 
samples to validate the microarray results in a technical control replicate. Therefore, we 
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investigated mRNA expression levels with normalization to the housekeeper gene Hprt. 
We were able to validate 9 out of the 12 selected candidates. Acvr1c was significantly 
upregulated in the good treatment responders after 28d of paroxetine treatment compared 
to the vehicle treated control group (T19 = -5.5570, p < 0.000) (Figure 24A). The same 
regulation pattern was found for Adra2c (T13.336 = -3.125, p < 0.01) (Figure 24B), C1ql2 
(T19 = -3.043, p < 0.01) (Figure 24E), Igfbp6 (T18 = -3.481, p < 0.005) (Figure 24G), 
Serpina3n (T11.903 = -2.891, p < 0.05) (Figure 24J), Serpinf1 (T11.658 = -3.421, p < 0.005) 
(Figure 24K) and Sox11 (T12.056 = -4.775, p > 0.000) (Figure 24L). However, we also 
detected genes that showed a significant downregulation in the good treatment responder 
after 28d of paroxetine compared to the vehicle treated control group, such as Cort (T18 = 
3.734, p < 0.005) (Figure 24D) and Pnck (T19 = 4.853, p < 0.000) (Figure 24I). Arsj (Figure 
24C), Drd1a (Figure 24F) and Mylk (Figure 24H) did not show any significant gene 
expression alterations between the two compared groups.  
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Figure 24: Validation of candidate genes from the microarray. From 12 selected candidates, the mRNA of 9 
transcripts were significantly regulated in the hippocampus after 28d of paroxetine treatment (A-L). * significant 
different to vehicle treated control animals p < 0.05. 
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3.3 Sox11 as a potential novel candidate mediating antidepressant action 
Evidences from the literature (Sha et al., 2012; Mu et al., 2012b; Kuhlbrodt et al., 1998; 
Jankowski et al., 2006; Haslinger et al., 2009) suggests a potential role of Sox11 in adult 
neurogenesis, thereby we selected Sox11 as a very interesting candidate for further 
investigations. Consequently, we were interested if different paroxetine treatment 
durations can also influence Sox11 gene expression. 
3.3.1 Chronic paroxetine treatment leads to a robust upregulation of Sox11 
To verify the upregulation of Sox11 after 28d of paroxetine treatment, brain samples 
originating from two independent experiments were used for ISH. The first samples 
derived from the microarray experiment, but were not selected for the microarray analysis 
itself. Here, we showed that paroxetine lead to a significant increase in Sox11 mRNA 
levels in the DG compared to the vehicle treated control group (T17 = -3.932, p < 0.005) 
(Figure 25A and C). We also investigated other hippocampal areas, but did not find a 
significant difference between the groups. After further evaluation Sox11 mRNA levels in 
the different responder groups, we were not able to detect a significant difference between 
good and poor responders. The second independent sample derived from chapter 3.1.5. 
Here, we also detected a significant difference in the DG between the treated animals 
(n=14) and the vehicle treated control group (n=20) (T32 = -6.283, p < 0.000) (Figure 25B 
and D). Additionally to the DG, we found a significant increase in Sox11 mRNA 
expression in the paroxetine treated animals in the CA1 region of the HC (T17.593 = -3.671, 
p < 0.01, vehicle: 11.75 ± 1.01; paroxetine: 21.34 ± 2.41). 
 
Figure 25: Sox11 mRNA expression after chronic treatment. (A-B) Chronic paroxetine treatment resulted in an 
increase in Sox11 mRNA expression levels compared to the vehicle treated control group. (C-D) Pictures show 
representative autoradiographs of Sox11 expression in the hippocampus of vehicle and paroxetine treated animals. 
* significant difference between vehicle treated control group and paroxetine treated group, p < 0.05. 
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3.3.2 Subchronic paroxetine treatment leads to higher Sox11 mRNA expression 
In a next step we were interested in the time course of paroxetine-induced regulation, i.e. 
the question whether Sox11 is already upregulated after subchronic treatment. Therefore, 
ISH was performed on brains obtained from chapter 2.2.4. After 14d of drug 
administration increased Sox11 mRNA expression levels were found in paroxetine treated 
animals (n=30) compared to the vehicle treated control group (n=12) (T40 = -2.958, p < 
0.01) (Figure 26A-B). A significant increase in Sox11 mRNA expression was also detected 
in the hippocampal CA1 region of the paroxetine treated animals (T40 = -2.875, p < 0.01, 
vehicle: 7.70 ± 0.92; paroxetine: 11.76 ± 0.81). 
 
 
Figure 26: Sox11 mRNA expression after subchronic treatment. (A) Subchronic paroxetine treatment resulted in 
increased Sox11 mRNA expression levels compared to the vehicle treated control group. (B) Pictures show 
representative autoradiographs of Sox11 expression in the HC of vehicle and paroxetine treated animals. * 
significant difference between vehicle treated control group and paroxetine treated group, p < 0.05. 
 
3.3.3 Acute paroxetine treatment does not alter Sox11 gene expression 
We could show that Sox11 is already upregulated after 14d of paroxetine treatment and 
this persists at least until 28d of paroxetine treatment. Subsequently, we were interested if 
this upregulation is already present after one acute dosage of paroxetine. Therefore, ISH 
was performed on brains obtain from chapter 2.2.1.3. Acute paroxetine administration has 
no influence on Sox11 mRNA expression in the HC (Figure 27). 
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Figure 27: Sox11 mRNA expression in the hippocampal DG after acute treatment. Acute paroxetine administration 
did not influence Sox11 mRNA expression levels.  
3.3.4 Sox11 upregulation is a SSRI specific effect 
We demonstrated in the previous chapters that paroxetine is regulating Sox11 mRNA 
expression in the mouse DG. Subsequently, we were interested whether the gene 
expression changes are SSRI specific effects or if the change in gene expression are due 
to antidepressants in general.  
Therefore, 25 male DBA/2J mice were treated twice a day for 28d with either vehicle 
(n=10) or 2 mg/kg BW reboxetine (n=15), a norepinephrine reuptake inhibitor (Figure 
28A). Regarding physiological parameters, reboxetine did not alter body weight gain 
between the vehicle and reboxetine treated animals (Figure 28B). Moreover, we did not 
detect any difference in corticosterone concentrations after chronic reboxetine treatment.  
However, chronic reboxetine administration was able to evoke a behavioral response in 
the FST. Reboxetine treated animals showed a significant increase in time struggling 
compared to the vehicle treated control animals (Figure 28C) (T22 = -4.301, p< 0.000) but 
interestingly vehicle treated animals showed a significant increase in time swimming (T22 = 
3.219, p < 0.005). No significant difference was found between the groups in time floating 
(Figure 28D). Nevertheless, reboxetine treated animals showed a significant increase in 
the latency to float in the FST (T21 = -2.316, p < 0.05) compared to the vehicle treated 
animals (Figure 28E). As depression often shows a high comorbidity with anxiety, we 
were also interested in the effects of reboxetine on anxiety-related behavior and therefore 
tested these animals in the DaLi. However, we did not detect any differences between the 
groups in anxiety-like behavior (Figure 28F).  
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In order to investigate the effects of reboxetine on Sox11 mRNA expression levels, ISH 
was performed. We did not detect any differences in Sox11 mRNA expression in the HC 
between vehicle and reboxetine treated animals (Figure 28G).  
  RESULTS 
 
58 
 
Figure 28: Physiological and behavioral effects of chronic reboxetine treatment. (A) Experimental time course. (B) 
Reboxetine did not alter body weight gain between the vehicle and reboxetine treated animals. (C) Chronic 
reboxetine administration was able to evoke a behavioral response in the FST. Paroxetine treated animals showed 
a significant increase in time struggling compared to the vehicle treated control animals. (D) No significant 
difference was found between the groups in time floating. (E) Reboxetine treated animals showed a significant 
increase in latency to float in the FST compared to the vehicle treated animals. (F) When investigating the effects of 
reboxetine on anxiety-related behavior in the DaLi, we did not detect any differences between the groups. (G) 
Reboxetine did not alter Sox11 mRNA expression levels. * significant difference between the vehicle treated control 
and the reboxetine treated group, p < 0.05. 
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3.3.5 Viral overexpression of Sox11 leads to a less anxious phenotype 
We could show a paroxetine-induced upregulation of Sox11 as well as the reduction in 
depressive-like behavior in the FST in the previous chapters. As a consequence, we 
examined whether a virus-mediated OE of Sox11 mimics the same behavioral phenotype 
as the paroxetine treatment. Therefore, we performed a region-specific OE of Sox11 in 
the hippocampal DG, by using AAV-9 Sox11OE (n=23) or empty control (n=20) injections 
(Figure 29C). ISH confirmed a stable overexpression of Sox11 in the DG region (T28 = -
8.835, p < 0.000) (Figure 29A-B), with some spreading in the CA3 region of the 
hippocampal formation (T13.507 = -18.105, p < 0.000). Furthermore, we additionally 
controlled for the viral OE by immunofluorescence (Figure 29D). 
 
Figure 29: Sox11 OE in the dorsal HC. (A) Sox11 mRNA expression levels in the dorsal HC. (B) Representative 
autoradiographs of Sox11 mRNA levels in the dorsal HC of control and Sox11 OE animals. (C) Schematic 
representation of the injection site (green). (D) Visualization of Sox11 expression in the HC 8 weeks after the 
injection of control (top row) and Sox11 OE (lower row). * significant difference between Empty control group and 
Sox11 OE group, p < 0.05. 
Animals were tested in the OF to investigate general locomotor activity. We could show 
that the viral overexpression of Sox11 did not change locomotor activity (Figure 30B). 
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Additionally, we analyzed the parameters of the inner zone in OF apparatus, which are 
also commonly used parameters to investigate anxiety-like behavior. Sox11 OE animals 
showed a reduced latency to enter the inner zone (T33 = 2.130, p < 0.05) (Figure 30C) as 
well as a longer distance travelled in the inner zone (T41 = -2.087, p < 0.05) (Figure 30D). 
Furthermore, they showed a tendency to spend more time in the inner zone (trend: T40 = -
1.944, p = 0.059). To verify this anxiety-like phenotype, we tested the animals additionally 
in the DaLi. Here, the Sox11 OE animals entered the light compartment more often 
compared to the empty control animals (T41 = -2.142, p < 0.05) (Figure 30E). Moreover, 
the Sox11 OE spent more time in the light compartment compared to the control animals 
(T41 = -2.521, p < 0.05) (Figure 30F). Sox11 OE animals also travelled more in the light 
compartment compared to their empty control group (T37.824 = -2.457, p < 0.05) (Figure 
30G).  
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Figure 30: Sox11 OE in the dorsal HC led to a less anxious phenotype. (A) Experimental time course. (B) Sox11 OE 
had no influence on general locomotion. (C) When analyzing the inner zone of the OF, Sox11 OE animals showed a 
reduced latency to enter the inner zone (D) as well as a longer distance travelled in the inner zone. (E) Viral OE of 
Sox11 led to a less anxious phenotype in DaLi compared to the empty control animals. Sox11 OE animals entered 
the light compartment more often compared to the Empty control animals. (F) Sox11 OE showed a significant 
increase in time spent in the light compartment compared to the control group. (G) Additionally, Sox11 OE travelled 
more in the light compartment compared to their Empty control group. * significant difference between Empty 
control group andSox11 OE group, p < 0.05. 
To investigate depressive-like behavior in these animals, we subjected them to a FST but 
no significant difference was found between Sox11 OE and the Empty control group 
(Figure 31A-B).  
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Figure 31: Sox11 OE had no effect on depressive-like behavior. (A) There was no significant difference between 
Empty and Sox11 OE animals in the time spent floating. (B) No significant difference was found between Empty 
and Sox11 OE animals in the time spent struggling. 
Additionally to the DaLi a NIH test was performed. However, we did not find any 
significant difference between the two groups in the NIH (Figure 32A-B). 
In order to exclude any cognitive deficits in these animals, we subjected them to a Y-
Maze. To investigate whether short-term memory performance is still intact in these 
animals, an inter-trail interval of 30min between the acquisition and the retrieval phase 
was applied. Both control and Sox11 OE animals performed better than chance level, as 
they spent significantly more time exploring the novel arm of the Y-Maze. However, we did 
not detect any difference between the two groups (Figure 32C-D).  
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Figure 32: Effects of Sox11 OE in the NIH and the Y-Maze. (A) No significant difference was found between the two 
groups in the latency to consume the sweetened condensed milk in the NIH. (B) Both groups consumed the same 
amount of sweetened condensed milk in the NIH. (C) Both testing groups performed better then chance level in the 
Y-Maze. Sox11 OE and Empty animals travelled more in the novel arm (D) and entered the arm more frequently 
compared to the already known arms. 
3.3.6 Sox11 OE and its influence on neurogenesis  
As there are evidences from the literature that Sox11 is involved in neurogenesis 
(Haslinger et al., 2009), we were interested, whether a region-specific overexpression of 
Sox11 in the DG also increases the neurogenesis rate. Therefore, 23 male DBA/2J mice 
were injected with either an AAV9-Sox11OE or AAV9-empty. After 4 weeks of recovery, 
the animals were then injected on 3 consecutive days with 100mg/kg BrdU pulse (Figure 
33A). 16 animals (Sox11OE n=8; Empty control n=8) were perfused on the last day of the 
BrdU pulse, 2 hours after the last injection (Figure 33A). This time point was chosen to 
analyze the proliferation rate as a consequence of the viral OE of the Sox11. However, we 
were not able to detect any differences in BrdU positive cells between the groups. Sox11 
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OE has no influence on the proliferation rate of NSPCs compared to the Empty control 
animals (Figure 33B-D). 
 
Figure 33: Influence of Sox11 OE on neurogenesis. (A) Experimental time course. (B) Sox11 OE had no influence on 
proliferation status. (C) BrdU immunoreactivity in the dentate gyrus 2 hours after the last BrdU pulse. (D) 
Visualization of Sox11 expression in the hippocampus of control (top row) and Sox11 OE (lower row) 4 weeks after 
the surgery (Scale: 1µm = 4.818pixel). 
7 animals (Sox11OE n=4; Empty control n=3) were perfused 28d after the last day of the 
BrdU pulse (Figure 34A). This time point was chosen to analyze the maturation status as 
a consequence of the viral OE of the Sox11. However, we did not detect any differences 
in the percentage of BrdU+ and NeuN+ cells in the BrdU+ labeled cells between the 
groups. The percentage of novel produced neurons (NeuN+ labeled cells, as NeuN is a 
marker for neurons) was the same in the compared groups. In order to test, whether an 
overexpression of Sox11 is leading in general to a higher number of BrdU+ cells and thus 
more cells, further staining and investigations needs to be performed. However, at this 
stage we can say, that within the novel produced cells (BrdU+ cells), there is no difference 
in NeuN+ labeled cells between the groups (Figure 34B).  
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Figure 34: Influence of Sox11 OE on neurogenesis. (A) Experimental time course. (B) Sox11 OE had no influence on 
proliferation status. 
 
3.3.7 Viral knockdown of Sox11 in combination with paroxetine treatment 
Sox11 OE seems to be an important factor in modulating anxiety-related behavior, as we 
could show in the previous chapter. Consequently, we performed a Sox11 KD to further 
elucidate its role in anxiety-like behavior and even more, whether paroxetine is able to 
reverse this hypothesized phenotype. Therefore, we performed a region-specific KD of 
Sox11 in the dorsal DG, by using an AAV-1/2 (n=35) or an SCR control (n=34) injection 
(Figure 35C). ANOVA analysis revealed a significant downregulation of Sox11 in the DG 
region (F1,36 = 12.674, p < 0.001) (Figure 35A, B), with some spreading in the CA3 region 
of the hippocampal formation. KD efficiency in the DG was 30%.  
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Figure 35: Sox11 KD in the dorsal hippocampus. (A) Sox11 mRNA expression levels in the dorsal HC. (B) 
Representative autoradiographs of Sox11 mRNA levels in the dorsal HC of vehicle and paroxetine treated animals 
as well as SCR control and Sox11 KD animals. (C) Schematic representation of the injection site (green). # 
significant ANOVA condition effect, p < 0.05. 
We detected an increase in body weight gain after paroxetine treatment in the previous 
experiments. Therefore, we were also interested in this parameter after 28d of paroxetine 
treatment under Sox11 KD and control conditions. ANOVA analysis revealed a significant 
treatment effect in the paroxetine treated animals compared to the vehicle treated control 
group, independent of the condition (F1,43 = 10.264, p < 0.01) (Figure 36B). To analyze 
whether the Sox11 KD lead to any locomotor changes, we subjected the animals to the 
OF. ANOVA analysis revealed a significant treatment effect (F1,43 = 4.887, p < 0.05) but no 
condition or condition x treatment interaction effect (Figure 36G). Further, paroxetine 
treated animals were less immobile in the OF compared to vehicle treated animals (F1,43 = 
4.585, p < 0.05, Sox11 OE vehicle: 169.22sec ± 21.76; Sox11 OE paroxetine: 148sec ± 
10.55; SCR vehicle: 169.22sec ± 27.84; SCR paroxetine: 145.49sec ± 18.38).  
As Sox11 OE led to a less anxious phenotype, we hypothesized that Sox11 KD would 
lead to a more anxious phenotype. Additionally, we were interested whether a chronic 
paroxetine treatment is able to reverse this effect. Therefore, we tested the animals in the 
DaLi. ANOVA analysis revealed a condition effect in the parameters distance in the light 
compartment (F1,46 = 4.180, p < 0.05), entries in the light compartment (F1,46 = 24.290, p < 
0.05) (Figure 36E) as well as time in the light compartment (F1,46 = 4.479, p < 0.05) (Figure 
36F). Paroxetine treatment did not influence anxiety-related behavior in this test. In order 
to investigate, depressive-like behavior in these animals we subjected them in a FST. 
ANOVA revealed that paroxetine treated animals showed significantly more time 
struggling compared to vehicle treated animals (F1,42 = 23.222, p < 0.000) (Figure 36C). 
This effect was independent of the genetic manipulation. Furthermore, we found that 
paroxetine treated animals floated significantly less time compared to vehicle treated 
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animals (F1,42 = 22.967, p < 0.000) (Figure 36D) and showed a longer latency to float (F1, 41 
= 8.305, p < 0.01) (Sox11 KD vehicle: 90.32sec ± 8.61; Sox11 KD paroxetine: 110.45sec 
± 13.10; SCR vehicle: 81.65sec ± 9.35; SCR paroxetine: 112.12sec ± 7.64). 
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Figure 36: Physiological and behavioral effects of Sox11 KD. (A) Experimental time course. (B) Paroxetine led to an 
increase in body weight gain compared to vehicle treated animals, independent of the genotype. (C) Paroxetine led 
to more time struggling in the FST compared to vehicle treated animals, independent of the genotype. (D) 
Paroxetine led to a decrease in time floating compared to vehicle treated animals, independent of the genotype. (E) 
Viral KD of Sox11 led to a more anxious phenotype in DaLi compared to the empty control animals, whereas 
paroxetine was not able to reverse this effect. (F) When comparing entries in the light compartment, no significant 
difference could be found between the groups. (G) Paroxetine treated animals showed a higher general locomotor 
activity compared to vehicle treated control animals. This effect is independent of the condition. # overall ANOVA 
condition effect, p < 0.05, § overall ANOVA treatment effect, p < 0.05 
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During this study, we detected a higher mortality rate in the Sox11 KD animals, reflected 
by 9 (of 35) compared to 0 (of 34) in the SCR control animals (Fisher's exact test: p < 
0.005).  
3.4 Genes and pathways mediating an early onset of antidepressant 
response 
The previous studies demonstrated that a 28d treatment regiment is well-suited to detect 
novel antidepressant-responsive genes. However, in order to differentiate between good 
and poor responders and even more to identify potential candidates mediating a more 
rapid onset of action, a shorter treatment period may be more promising. There is 
evidence from clinical studies, that some patients start responding to an antidepressant 
treatment already after 14d of antidepressant administration (Papakostas et al., 2006). 
According to this finding, we treated 140 male DBA/2J mice subchronically (14d) with 
5mg/kg BW paroxetine (n=90) or vehicle (n=50) (Figure 37A). 
To analyze the effects of subchronic paroxetine treatment on physiological parameters, 
body weight gain was assessed in these animals. 14d of paroxetine treatment (5mg/kg 
BW) led to a significant increase in body weight gain in the paroxetine treated animals 
compared to the vehicle treated animals (T105 = -8.356, p < 0.000) (Figure 37B). However, 
a subchronic paroxetine treatment did not significantly reduce corticosterone levels in the 
paroxetine treated animals compared to the vehicle treated control group. (Figure 37C).  
We also investigated paroxetine brain and plasma levels after a subchronic treatment. 
ANOVA analysis showed a significant increase in plasma paroxetine concentrations in 
good responders compared to the intermediate responder group and the poor responder 
group (F2,25 = 3.691, p < 0.05). Further post-hoc analysis revealed a trend between good 
responders compared to the intermediate responder group and the poor responder group. 
No significant difference was found between the intermediate and the poor responder 
groups (Figure 37D). The same pattern was detected for paroxetine brain concentrations. 
Good responders showed significantly higher brain paroxetine concentrations compared 
to the intermediate responders and the poor responders (F2,32 = 7.777, p < 0.01). Further 
post-hoc analysis revealed a significant difference between good responders compared to 
the intermediate responder group and the poor responder group. No significant difference 
was found between the intermediate and the poor responders (Figure 37E). However, 
paroxetine brain and plasma concentrations were highly correlated (r = 0.554, p < 0.000) 
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(Figure 37F). For the here presented correlation analysis, we only analyzed poor and 
good responders.  
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Figure 37: Neuroendocrine, physiological and pharmacological parameters after subchronic paroxetine treatment. 
(A) Experimental time course. (B) Paroxetine treated animals showed a significant increase in body weight gain 
compared to vehicle treated animals. (C) No difference was found in corticosterone levels between the groups. (D) 
Good responders showed significantly higher plasma paroxetine levels compared to poor and intermediate 
responders. (E) Good responders showed significantly higher brain paroxetine levels compared to poor and 
intermediate responders. (F) Paroxetine brain and plasma concentrations highly correlated with each other. * 
significant difference between vehicle treated control group and paroxetine treated group, p < 0.05. 
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To investigate the responder status within the paroxetine treated group, we subjected the 
animals to a FST. Overall, paroxetine treated animals showed significantly less time 
floating compared to vehicle treated control animals (T80.701 = 9.157, p < 0.000) (Figure 
38A and C). Furthermore, paroxetine treated animals also showed more active behavior 
compared to vehicle treated animals. The time swimming was increased in paroxetine-
treated animals (T105 = -5.112, p < 0.000, vehicle: 112.05sec ± 4.74; paroxetine: 
147.80sec ± 4.99;) as well as the time struggling (T102.624 = -4.496, p < 0.000) (Figure 
38B).  
 
Figure 38: Subchronic paroxetine treatment led to a less depressive-like behavior in the FST. (A) Paroxetine treated 
animals showed less time floating compared to vehicle treated animals. (B) Paroxetine treated animals showed 
higher time floating compared to vehicle treated animals. (C) Identification of different responder groups according 
to their performance in the FST. Animals indicated in the red squares are referred as good and poor treatment 
responder. Animals that showed a very high time floating represent the poor treatment responder, whereas animals 
that showed a very low time floating represent the good treatment responder. Animals indicated in the green dotted 
square are representing internal control groups. The animals within the paroxetine treated group are representing 
the intermediate responder group and served as a treated control group. The animals within the vehicle treated 
group served as a vehicle treated control group. * significant difference between vehicle treated control group and 
paroxetine treated group, p < 0.05. 
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3.4.1 Brain Microarray analysis 
The animals used for the Microarray analysis were part of the in the previous chapter 
described cohort. As we were aiming to identify novel genes and pathways determining 
early antidepressant response, we were interested in the individual time floating in the 
FST of these animals. After identifying good (n=12), poor (n=12) and intermediate (n=8) 
treatment responders as well as the vehicle treated control group (n=12) (for detailed 
information see 2.5) a whole-genome expression microarray was conducted with 
hippocampal brain tissue (Figure 38C). Analysis of the Illumina microarray chip revealed 
101 differently regulated genes between vehicle treated animals and good responders at 
a false discovery controlled significant level of 10% (q < 0.1). Duplicates were removed in 
a next step (n=10) as well as genes that were detected by the microarray but were not 
specific for the respected gene (n=4). Resulting in 87 differentially regulated genes. A 
detailed gene list containing all relevant parameters can be found in Table 5. There were 
no significant differences between good and poor treatment responders. 
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Table 5: Significantly regulated genes in the hippocampal DG region 14d after paroxetine treatment. Genes are 
ordered by their functional classes. Fold Changes were normalized to vehicle treated animals. 
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3.4.2 Identification of potential networks via pathway analysis in the hippocampus 
In order to identify novel genes and pathways that might play a role in mediating an early 
antidepressant response in DBA/2J mice, we performed a pathway analysis with the 87 
genes detected by the microarray. We identified a pathway formed out of 15 genes 
(Figure 39) that originated from the microarray result, after applying these genes to the 
Pathway Studio software v7.1 (Ariadne Genomics, Rockville, MD, USA), which contains 
literature-based relations between proteins, small molecules and cellular processes 
(Webhofer et al., 2011).  
 
Figure 39: Pathway analysis of altered genes after 14d of paroxetine treatment. 15 out of 87 genes were clustered in 
a common pathway via the Pathway analysis software. 
 
3.4.3 Validation of potential candidates with qRT-PCR 
After performing the pathway analysis, 14 genes were selected for further investigation. 
The samples derived from the microarray analysis were used for qRT PCR as technical 
control replicates. We investigated mRNA expression levels with normalization to Hprt. 10 
out of the 14 selected candidates could be validated. Bgn was significantly upregulated in 
the good responders after 14d of paroxetine treatment compared to the vehicle treated 
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control group (T22 = -2.141, p < 0.05) (Figure 40A). The same regulation pattern was 
found for Gfap (T11.360 = -2.553, p < 0.05) (Figure 40D), Serpinf1 (T17.725 = -2.730, p < 0.05) 
(Figure 40I), Slc14A1 (T13.506 = -2.289, p < 0.05) (Figure 40J), Vim (T21 = -2.835, p < 0.01) 
(Figure 40M), Wisp1 (T20= -2.789, p < 0.05) (Figure 40N). Good responders showed a 
trend in Cd9 upregulation compared to vehicle treated animals (T22 = -1.997, p = 0.058) 
(Figure 40B). However, we also detected genes that show a significant downregulation in 
the good treatment responders after 14d of paroxetine treatment compared to the vehicle 
treated control group, such as Cxcl12 (T22 = 2.2.39, p < 0.05) (Figure 40C),Il16 (T22 = 
3.319, p < 0.005) (Figure 40E), Ntf3 (T22 = 4.537, p < 0.000) (Figure 40G) and Trpc6 (T22= 
2.995, p <0.01) (Figure 40L). Mylk (Figure 40F), Ptpn21 (Figure 40H) and Stat3 (Figure 
40K) did not show any significant gene expression alterations between the two treatment 
groups.  
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Figure 40: Validation of candidate genes from the microarray. Out of 14 selected candidates, the mRNA of 10 
transcripts were significantly differently regulated in the hippocampus after 14d of paroxetine treatment (A-N). * 
significant different to vehicle treated control animals p < 0.05. 
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3.4.4 Time course of gene expression regulation during antidepressant treatment 
in the mouse hippocampus  
Interestingly, more genes were regulated following subchronic paroxetine treatment 
compared to chronic treatment. When comparing the gene expression profiles of the two 
treatment time points, we identified an overlap of 15 genes differently regulated following 
both treatment intervals (Table 6). The 15 detected genes in the overlap were equivalent 
to 17.2% of the total number of genes found after 14d of treatment and 50% of the genes 
detected after 28d of treatment.  
Table 6: Differently regulated genes after 14d and 28d of paroxetine treatment. When comparing the genes 
differently regulated after 14d and 28d, we detected an overlap of 15 genes, which were regulated after both 
treatment time points. 
 
 
3.4.5 Transcriptome signatures predicting antidepressant response in the 
periphery 
We aimed at the detection of novel genes and pathways in the periphery of DBA/2J mice 
mediating an early antidepressant response not only in the brain but also in the periphery. 
This could potentially provide novel information on individual antidepressant treatment 
outcome after subchronic treatment. Therefore, we conducted a whole-genome 
expression microarray analysis by using peripheral blood. For this purpose gene 
expression data sets of vehicle treated animals (n=12), good responders (n=12) and poor 
responders (n=12) were created and analyzed. In pairwise group comparisons both 
treatment effect and response status of mice were evaluated in respect to antidepressant 
treatment. Technical batch effects in the data set and measured drug concentrations in 
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blood were used as covariates in an ANOVA based statistical model. Although no robust 
gene regulation was apparent when comparing treatment groups (independent of 
response) with the control group. However, there was a pronounced effect within the 
treatment group. Interestingly, we were able to detect a set of 259 transcripts that show a 
significant change in expression due to antidepressant response status at a false 
discovery controlled significance level of 10% (q < 0.1) (Table 7).  
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Table 7: Significantly regulated genes in the peripheral blood between good and poor responders after 14d of 
paroxetine treatment. Genes are ordered according their functional classes. Fold changes are normalized to poor 
responders. 
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Out of those 259 differentially regulated probes, 13 transcripts were chosen for qRT-PCR 
validation (Table 8). The selection of the candidates was based on literature research.  
We were able to validate 2 candidates out of the preselected targets with two different 
housekeepers (Hprt and Rpl18a). Add1 was significantly down regulated in the good 
treatment responders compared to the poor treatment responders (Hprt: T22 = 4.001, p < 
0.005; Rpl18a: T22 = 2.762, p < 0.05) (Figure 41A). The same expression pattern was 
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found for P2rx1. P2rx1 was significantly down regulated in the good treatment responders 
compared to the poor treatment responders (Hprt: T21 = 4.199, p < 0.000; Rpl18a: T20 = 
2.288, p < 0.05) (Figure 41B).  
 
Figure 41: Validation of candidate genes from the microarray. (A) Add1 was significantly down regulated in good 
treatment responders compared to poor treatment responders. (B) P2rx1 was significantly down regulated in good 
treatment responders compared to poor treatment responders. * significant different to good treatment responders 
p < 0.05. 
Table 8 shows the results for all preselected gene for both microarray and qRT-PCR 
results.  
Table 8: Comparison of the microarray and the qRT-PCR data. Genes that were significantly regulated in the 
microarray and the qRT-PCR are printed in bold. Fold changes were normalized to poor responders. 
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3.4.6 Predictive gene expression transcripts of antidepressant treatment response 
tested in a human sample  
To assess the relevance of the gene expression transcripts for antidepressant response in 
humans, we tested their predictive ability to classify response status in a human sample. 
The sample (n=38), consisted of a subset of MDD patients treated with escitalopram for 
12 weeks. These patients were recruited from two samples at Emory University School of 
Medicine (Department of Psychiatry and Behavioral Sciences). The first sample (n= 32) is 
a small subset of the PReDICT study (Dunlop et al., 2012), containing four hundred 
treatment-naive patients with MDD diagnosis. The second sample (n=6), also a subset of 
a previously published study (McGrath et al., 2013) consisted of patients with a primary 
diagnosis of MDD (assessed by the Structured Clinical Interview for DSM-IV-TR Axis I 
Disorders, Research Version, Patient Edition With Psychotic (Screen) (First MB, 2002) 
who were randomly assigned to 12 weeks of either escitalopram or cognitive behavioral 
therapy for 12 weeks. From both samples blood was drawn at baseline and after 12 
weeks. Only patients from the drug groups (n=38) were included in the final analysis. 
From our full drug-treated sample, 27 patients were classified as responders and 11 as 
non-responders according to percent changes in HDRS-17 scores from baseline to week 
twelve (≥ 50% or < 50% change respectively). 
Mouse gene expression transcripts (n=259) were mapped to its human orthologue genes 
present in the Illumina HT-12 arrays (n = 241). Gene expression repeated measures from 
the patients at baseline and week 12 were available, thus we computed the absolute 
difference between the expression levels of the transcripts between those time-points and 
tested whether these alterations were able to predict response to escitalopram treatment. 
Interestingly, we were able to detect differences in expression profiles from baseline to 
week 12 of the human-orthologues that allowed us to predict the response status (percent 
change in HDRS-17 from baseline to week 12) with an accuracy of 84% in the human 
sample. Prediction persisted after we permuted the response-status labels 1000 times (p 
= 0.017).  
3.4.7 ENCODE ChIP-Seq enables us to detect common transcription factors, 
regulated by the gene set predicting antidepressant response in humans 
Using the ENCODE ChIP-Seq Significance Tool 
(http://bioinformatics.oxfordjournals.org/content/early/2013/06/02/bioinformatics.btt316.full.
pdf+html), we checked for transcription factor enrichment among our genes identified in 
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our analysis. Enrichment scores for this tool are calculated using a one-tailed 
hypergeometric test that is corrected for multiple testing using false discovery rate 
(Auerbach et al., 2013). For instance, the CCCTC-binding factor (CTCF) was one of the 
transcription factors enriched in our analysis. Out of the 183 mouse genes recognized in 
the database, 149 genes were regulated by CTCF within a 500 base pair radius of their 
respective transcription start sites ( p = 3.845 * 10 ^ -77). The effect of this transcription 
factor was replicated in the human ortholog sample as 145 of the 236 genes recognized 
by the server were similarly regulated by CTCF (p = 2.44 * 10 ^ -6). Thus, the genes 
identified in our analysis are closely linked by CTCF transcription factor regulation, 
indicating a common mechanism.  
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4 Discussion 
 
Depressive disorder is one of the most common mental diseases worldwide. However, 
when it comes to antidepressant treatment outcome, a significant number of patients do 
not show an adequate response to the treatment, relapse or continue to show remaining 
symptoms (Trivedi et al., 2006). The overarching aim of this thesis was to advance our 
current understanding of the neurobiology underlying individual antidepressant treatment 
response in major depression, and to furthermore identify predictors of treatment 
outcome. A number of studies have already aimed to identify valid biomarkers, which 
would allow the clinicians to predict antidepressant treatment outcome (Schmidt et al., 
2011a; Cattaneo et al., 2013; Le-Niculescu et al., 2008a; Leuchter et al., 2010; Leuchter 
et al., 2009; Binder and Holsboer, 2006; Schwarz and Bahn, 2008). However, the results 
in such studies were rather disappointing. In search of confounding factors impairing the 
identification of response biomarkers in MDD, the following factors, amongst others, have 
been identified as being important. First, the unreliability of the diagnosis is a critical point 
for clinical studies, and is founded on the basis that depression is a complex syndrome, 
and not simply a disease entity (Rush, 2007). Different symptoms of the syndrome, such 
as sleep disturbances, lack of concentration and depressed mood may all have 
biologically distinct causes. Second, individual confounding environmental factors are 
likely to play a critical role in biomarker research. It is now generally accepted that 
susceptibility to major depression is determined by a combined effect of genes and 
environment, with heritability estimates ranging from 30% to 40%, complemented by a 
major impact of stressful or aversive life events (Villanueva, 2013; Malhi et al., 2000; 
Nestler et al., 2002a). Changes in epigenetic modifications during the lifespan as a 
consequence of a plethora of environmental influences, including previous disease 
episodes and treatment schedules, are also likely to hamper the identification of valuable 
predictive biosignatures for treatment response (Klengel et al., 2014; Dell'Osso et al., 
2014; Pena et al., 2014; Nestler, 2014). Third, the heterogeneity of the patient’s age in 
clinical studies is likely to be a critical point for the identification of biomarkers. To 
overcome these limitations, which are characteristics of any human experimental trail, we 
developed a novel experimental approach that mimics the heterogeneity of antidepressant 
treatment outcome in mice, which is already known from the clinical situation. 
Using this novel experimental approach, we provide a large body of evidence that the 
here described animal model is a valid model, depicting the heterogeneity of 
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antidepressant treatment outcome in mice, and is therefore a good approach to 
investigate targets mediating individual antidepressant responses. After extensive 
validation of our experimental approach, we combined our model and findings from the 
clinical situation, in order to identify a subgroup of mice who responded well and poorly 
after a chronic and subchronic pharmacological treatment. Gene expression differences in 
the good responder and poor responder subgroups were extensively analyzed using an 
unbiased microarray approach, aiming to identify novel targets and gene networks 
mediating the antidepressant treatment outcome. After the chronic antidepressant 
treatment, we were not able to detect any significant differences in gene expression 
between good and poor treatment responders. However, after 14d of paroxetine 
treatment, we identified a gene expression signature in the peripheral blood that was able 
to predict the antidepressant response in our mouse model. Furthermore, these findings 
enabled us to predict the response status within a subset of human patients. 
Additionally, we were able to identify and further characterize Sox11 as one of the most 
interesting candidate genes regulated during antidepressant treatment in the mouse brain. 
Specifically, chronic and subchronic antidepressant treatment induces Sox11 mRNA 
expression in the hippocampal DG, and moreover our data suggests that Sox11 is 
involved in modulating anxiety-related behavior. 
4.1 Pharmacological studies 
The commonly prescribed antidepressants are generally effective, although a subset of 
patients do not respond to any prescribed interventions. Paroxetine, a SSRI, is used 
regularly in the clinic to treat depression and its pharmacology is well described in 
humans. Preskorn and colleagues could show that all SSRIs are slowly and fully absorbed 
from the gut with a peak plasma concentration after 3 - 8 hours. They could also 
demonstrate that a minimum effective dosage of 20mg/day paroxetine is eliminated in the 
human with a half-life of 1 day (Preskorn, 1997). The pharmacokinetics and 
pharmacodynamics of paroxetine in the mouse have so far not been described in detail. 
This leaves the question about the correct and most importantly translatable dosage 
largely unanswered. As conclusive data are still not available from the literature, we 
conducted initial pharmacological studies. 
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4.1.1 Paroxetine - struggling for the right dosage 
First, we were interested in identifying the minimum effective dosage for the DBA/2J 
mouse strain, as we wanted to avoid any possibility of animal overdosing. Thus, we 
performed two independent studies where we tested two different concentrations of 
paroxetine in various parameters.  
In the beginning, we treated the animals chronically with a very low dose of paroxetine 
(1mg/kg BW twice a day) and detected a significant increase in body weight gain in the 
paroxetine treated animals compared to the vehicle treated control group. The same could 
be shown for the higher paroxetine concentration (5mg/kg BE twice a day) following 
chronic administration. These findings are in line with data from clinical studies, where an 
increase in body weight gain during antidepressant treatment is a common unwanted side 
effect (Flint and Kendler, 2014). Antidepressants not only influence body weight, but also 
have been consistently described to attenuate the HPA system (Holsboer, 2003; Holsboer 
and Barden, 1996). More than 30 years ago, Gibbons and colleague could demonstrate 
that plasma cortisol levels are elevated in depressed patients and are furthermore 
normalized after clinical remission (Holsboer and Barden, 1996; Gibbons, 1964). Other 
studies have demonstrated that untreated depressed patients show exaggerated cortisol 
release after Dex stimulation compared to healthy controls in a combined dexamethasone 
(Dex)/CRH-test, a common test to investigate changes in stress system function. 
Interestingly, after 1 week of amitriptyline treatment these abnormalities began to 
disappear and normalization of the HPA axis becomes even more pronounced after a 
longer antidepressant treatment period (Heuser et al., 1996). Furthermore, Ising and 
colleagues have demonstrated that patients presenting a significant reduction in stress 
hormone levels already after 2 weeks of antidepressant treatment, show a more 
pronounced reduction in the Hamilton Rating Scale for Depression (HDRS) after 5-6 
weeks of treatment. Therefore, they found that an improvement in the Dex/CRH test after 
2 weeks of antidepressant treatment was significantly associated with treatment response 
5 weeks after a pharmacological intervention (Ising et al., 2007). Besides these clinical 
studies, there is also evidence from preclinical studies, in which a correlation between the 
dysregulation of the HPA system and the psychopathology of depression has been shown 
(reviewed in (Holsboer and Barden, 1996)). Reul and his coworkers also observed that 
chronic antidepressant treatment is able to reduce basal as well as stress-induced 
corticosterone (equivalent to cortisol in the human system) levels (Reul et al., 1993). 
Considering these findings all point to a central link between antidepressant treatment and 
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HPA axis regulation, we also examined corticosterone levels after chronic antidepressant 
treatment. When the low paroxetine dose was administered, we were not able to find a 
significant difference between paroxetine and vehicle treated animals. This low paroxetine 
dosage seems to influence physiological parameters, namely body weight gain, but is not 
able to evoke an attenuation of the HPA system in the DBA/2J mouse strain. However, 
the higher paroxetine concentration was able to attenuate the HPA axis reactivity, 
resulting in lower corticosterone levels in the paroxetine treated animals, which is in 
agreement with previous findings. Here, our novel animal model reproduced the same 
phenotype as numerous clinical studies including a reduction of stress hormone levels 
after antidepressant administration (Heuser et al., 1996; Ising et al., 2007; Shimoda et al., 
1988).  
Besides the physiological and neuroendocrine changes, antidepressant treatment should 
also provoke a robust behavioral phenotype, which has already been highlighted in 
various preclinical studies (Sillaber et al., 2008; Webhofer et al., 2011; Nestler and 
Hyman, 2010; Nestler et al., 2002b). At a concentration of 1mg/kg BW, paroxetine-treated 
animals tended to spend less time floating in the FST compared to vehicle-treated mice, 
but neither the time spent swimming or the time spent struggling was significantly different 
between the groups. These behavioral data indicate that at 1mg/kg BW, the concentration 
of paroxetine was too low to provoke robust behavioral and neuroendocrine phenotypes. 
By contrast, chronic paroxetine treatment administered at the higher dose was able to 
effectively provoke robust behavioral responses in the FST. Paroxetine-treated animals 
spent less time floating and more time engaged in active behaviors, namely swimming 
and struggling. These behavioral findings are in line with various other studies, which 
have demonstrated that antidepressant treatment leads to an increase in active behavior 
and a decrease in passive behavior in the FST (Sillaber et al., 2008; Webhofer et al., 
2011).  
In order to gain insight into the pharmacology of the two different antidepressant doses 
administered to the mice, paroxetine levels were measured in the brain and the plasma of 
the paroxetine-treated animals. At a concentration of 1mg/kg BW paroxetine, no 
significant difference was found in paroxetine plasma or paroxetine brain concentrations 
between the different responder groups, thereby ruling out that the individual differences 
in treatment efficacy was a consequence of different drug concentrations. Additionally, we 
could demonstrate that paroxetine brain and plasma concentrations are highly correlated. 
Nevertheless, it is important to acknowledge that the measured plasma paroxetine 
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concentrations, with an average of 50ng/ml, are relatively low compared to the human 
situation, showing average values of 180ng/ml (Heuser et al., 1996). Similarly, at the 
higher dose of paroxetine no significant difference was detected in paroxetine plasma and 
brain concentrations between the different responder groups. Plasma and brain 
paroxetine concentrations were significantly higher compared to the previously used 
1mg/kg BW dose. We could show again a correlation of paroxetine brain and plasma 
concentrations. 
In summary, we conclude that a concentration of 1mg/kg BW paroxetine is insufficient to 
evoke robust behavioral and neuroendocrine treatment effects in our experimental model. 
By contrast, chronic administration at 5mg/kg BW is sufficient to evoke robust behavioral 
and neuroendocrine treatment effects in our experimental model and was therefore 
selected for all further experimental investigations. 
Does a subchronic paroxetine treatment evoke the same physiological profile as a 
chronic treatment? 
Treatment duration is another important issue in any experimental design. We therefore 
addressed the question as to whether a subchronic (14d) treatment is sufficient to elicit 
the same behavioral and physiological phenotype compared to that resulting from chronic 
treatment. After 14d of paroxetine treatment we detected an increase in body weight gain, 
which is in line with our physiological data following chronic paroxetine treatment. 
However, it was not accompanied by a reduction in corticosterone levels. One can 
speculate that a treatment duration of 14d is too short to significantly modulate HPA axis 
activity, as has been shown by Reul and co-workers to occur following chronic treatment 
(Reul et al., 1993).  
Antidepressants are known to alter the behavior of an animal in the FST. After subchronic 
paroxetine treatment we detected the same behavioral phenotype that manifested 
following chronic paroxetine treatment. Treated animals showed a reduction in the time 
spent floating and an increased time engaged in active behaviors. These behavioral data 
indicate that subchronic antidepressant treatment is sufficient to evoke robust behavioral 
phenotypes.  
We next checked whether treatment response (good versus poor responders) correlates 
with plasma/brain paroxetine concentrations. Interestingly, plasma paroxetine 
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concentrations were significantly elevated in good responders compared to the 
intermediate responder group and the poor responder group. The same pattern was found 
for brain paroxetine concentrations. This significant difference in brain and plasma 
paroxetine concentrations could be a reasonable explanation, as to why some animals 
show a rapid and strong antidepressant response in the FST while others do not. 
However, in the subsequent microarray analyses on these animals, plasma paroxetine 
concentrations were considered as co-variate, and were excluded to play a significant role 
here (see chapter 3.4.4 - 3.4.7). There is evidence from clinical studies that 
polymorphisms in specific blood brain barrier transporters, such as ABCB1, are involved 
in a better and faster antidepressant response (Uhr et al., 2008). As we used an inbred 
mouse strain in our experiment, genetic polymorphisms are not likely to play a prominent 
role here. However, differences in gene expression regulation of specific blood brain 
barrier transporters, resulting from antidepressant treatment, may provide an explanation 
for the significant difference in brain paroxetine concentrations. Therefore, gene 
expression analysis for drug transporters at the blood-brain-barrier could be performed in 
future studies, in order to investigate their potential involvement in shaping the behavioral 
response. Nevertheless, further studies are need in order to elucidate the molecular 
mechanisms underlying the early response phenotype in these animals. 
4.1.2 Elimination kinetics of paroxetine - can we really translate from men to 
mouse? 
After we had identified the minimum effective dosage for the DBA/2J mouse strain, we 
aimed to gain a better understanding into the pharmacokinetics of paroxetine, especially 
with regards to the pharmacological half-life within the mouse organism. Therefore, male 
DBA/2J mice were treated chronically with 5mg/kg BW paroxetine twice daily and were 
subsequently killed at different time intervals after discontinuation of the paroxetine 
treatment. In a clinical study it has been shown, that a single dose of paroxetine 
administration (20mg) is eliminated with a half-life time of 10h in adult men. In the same 
study, multiple administrations of paroxetine (20mg/day) resulted in decreased elimination 
rates and a longer half-life time of 24h (Kaye et al., 1989). Here, we were able to show 
that the elimination rate following chronic paroxetine treatment in a mouse was similar to 
the elimination rate of multiple administrations of paroxetine in humans. One day after 
discontinuation of the antidepressant, the animals showed a 50% reduction in the 
paroxetine levels, which is in line with the human situation. Additionally, we could prove 
here that paroxetine plasma levels are no longer detectable 3 days after discontinuing 
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antidepressant treatment. As there is only limited access to the brain in human studies, 
we also investigated the paroxetine half-life in the mouse brain. We have shown that 
paroxetine brain and plasma concentrations are highly correlated, which has important 
clinical implications given the inability to assess human brain concentrations. We clearly 
demonstrated that paroxetine levels, which are measured in the blood, reflect the situation 
in the brain. Furthermore, we showed that paroxetine is detectable slightly longer in the 
brain, although there is nevertheless very little left 3 days after discontinuing paroxetine 
treatment. 
Taken together, we have shown that paroxetine plasma and brain levels are highly 
correlated. Furthermore, we demonstrated that the elimination rate of paroxetine in the 
mouse is the same as what is observed in the human situation. These findings could 
serve as a basis to predict brain concentrations within clinical studies and enable us to 
really translate our pharmacological studies from the mouse to the human system. 
4.1.3 Mouse pellets - one step closer to translational research 
Gavaging, i.p. injection as well as oral administration via the drinking water are all 
common tools for drug application in preclinical sciences (Wagner et al., 2012; Santarelli 
et al., 2003; Ganea et al., 2012; Hodes et al., 2010; Qi et al., 2008). However, such routes 
of administrations are accompanied by certain limitations. For example, gavaging and i.p. 
injection are very time consuming techniques, especially when performed on a large 
number of animals. In addition, they are a very stressful for the animals and the animals 
need to be handled on a daily basis. Most of the time body weight loss accompanies 
these procedures (Atcha et al., 2010; Zhang, 2011; de Meijer et al., 2010), which is a 
reflection of the animal's discomfort, and can thus be interpreted as an additional stressful 
stimulus. Drug administration via drinking water also has its limitations. For examples, the 
researcher does not retain control of the exact amount of drug consumed by the 
experimental animal. Although the bottles are weighed on a regular basis, leakage cannot 
be completely prevented and thus calculation of the exact dose is not always accurate. 
Secondly, the concept of peak-trough, dosing as achieved by the administration of mouse 
pellets, cannot be achieved from continuous administration of the compound via the 
drinking water, as chosen in other rodent studies. However, the route of administration is 
an important consideration when designing a valid animal model that mimics the human 
situation. For example, there is good evidence to believe that pharmacokinetics play an 
important role when it comes to the regulation of gene expression (Schug et al., 2013). 
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This study is, to our knowledge, the first to use customized mouse pellets for drug 
administration. These pellets bring us one step closer to translational research, as nearly 
all patients receive their antidepressants via tablets. Besides the fact that this approach 
will bring us closer to clinical research, the mouse pellets have additional advantages. The 
use of pellets represents a non-invasive drug delivery system, as the pellets are simply 
dropped in the animal's home cage and the animals are totally free to consume these 
pellets. Moreover, the pellets are a highly palatable food for the animals, and they 
consume it within the first minutes, and therefore this type of administration represents a 
stress-free route of delivery. To ensure that administration of mouse pellets is comparable 
to the commonly used i.p. injection, 10 male mice were injected with one acute 5mg/kg 
BW dosage of paroxetine. Animals administered paroxetine via i.p. injections presented 
significantly higher plasma paroxetine levels and higher brain paroxetine levels compared 
to the animals treated with the mouse pellet. In addition, paroxetine brain and plasma 
levels after i.p. injection were also highly correlated. Clinical studies have shown that after 
chronic paroxetine administration the maximum plasma concentration is around 105µg/ml 
(Heydorn, 1999). Therefore, we conclude that although we detected a significant 
difference between the two application forms, the paroxetine plasma levels of the mouse 
pellets are still in a similar pharmacological range compared with the human situation. 
4.2 Novel experimental approach - modeling individual antidepressant 
response in mice 
The identification of novel biomarkers in depression has been relatively unsuccessful in 
clinical studies, so far (Schmidt et al., 2011a; Sim and Ingelman-Sundberg, 2011). The 
reasons for this are not yet clear. Human genetic studies are searching for chromosomal 
regions or candidate genes that play a role in mood regulation and/or other 
neuropsychiatric disorders. To-date, the clinical data is rather disappointing since the 
human data sets are very heterogeneous as they are influence by many co-factors, 
including different drugs, ages, disease history, and a variety of environmental influences 
that very likely impact gene expression (epigenetic factors) ((Le-Niculescu et al., 2008a) 
and reviewed in (Philibert et al., 2014)). In contrast, animal models are mainly performed 
with homogeneous inbred mouse strains in controlled environments. This overcomes 
some limitations associated the human studies. However, animal studies are often lacking 
in terms of relevance to the human condition (Le-Niculescu et al., 2008b). Depression is a 
very complex psychiatric disorder (Kessler et al., 2005; Nestler et al., 2002a), and it's 
diagnosis is already challenging enough in humans. Translating this complex human 
DISCUSSION   
 
97 
disorder into an animal model approach is even more challenging. The ideal animal model 
should fulfill certain criteria: it should mimic the human conditions with regard to 
symptomatology, pharmacological treatment and the biological basis (McKinney et al., 
1969). However, meeting all these criteria is very difficult, especially in depression where 
some key features (worthlessness, guilt and suicidal intention) are defined by a subjective 
verbal report, which can never be modeled in animals (Sillaber et al., 2009). Furthermore, 
the most commonly used animal models are non-primate, often rodents, and are based on 
exposing a healthy animal to a stressful environment. These models then only account for 
experienced-related behavioral changes in depression (Kalueff et al., 2007). Some 
aspects, such as the influence of genetic variations are completely ignored in these 
models and thus the development of the ideal homologous model seems out of reach 
(Sillaber et al., 2009). As depression is a very complex disease, only certain key 
symptoms, such as anhedonia, dysregulation of the HPA axis and altered brain 
morphology, can be mimicked (Sillaber et al., 2009). DBA/2J represent an inbred mouse 
strain with an high innate anxiety and a high responsiveness to antidepressant treatment 
under basal condition (Ohl et al., 2003; Yilmazer-Hanke et al., 2003), and was thus 
selected as the ideal mouse strain for our experimental approach. By using this mouse 
strain, we avoided the use of additional stressors, which would have been needed in other 
mouse strains to evoke an antidepressant treatment response. In this experimental 
design, we just focused on individual antidepressant treatment response in mice. 
Moreover, this novel attempt should not be seen as a novel model for depression-like 
symptoms but rather as a means for modeling the heterogeneity of antidepressant 
treatment outcome, an issue of supreme importance in psychiatric care. By using an 
inbred mouse strain housed under the same conditions, we tried to control for all the 
above mentioned factors, which may potentially disguise biomarkers in the clinical 
situation. Our hypothesis is that this completely controlled animal model may enable us to 
detect 'super-clean' biomarkers, which we could then translate to the clinic. Preclinical as 
well as clinical studies are thus highly relevant for this field, and more importantly, must be 
combined to detect potential strong candidates that would otherwise be missed in the 
independent models (Le-Niculescu et al., 2008a). These novel targets can be then 
extensively investigated in the animal model and thus may shed light on the field of 
biomarkers in antidepressant treatment outcome (Figure 42). 
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Figure 42: Need for novel experimental approaches: strategies for improving translational research in the field of 
depression. To detect novel candidate genes and biomarkers that are also relevant for the clinical situation, 
improved animal experimental approaches need to be established. To enable a translational approach, questions 
that are arising in the daily clinical situation need to be precisely formulated and then translated in an animal 
approach. With this animal approach we are able to detect novel targets, especially in the brain, which are 
mediating the individual antidepressant response. Furthermore, we need to integrate the mouse data at a very early 
stage with the human data, which would then enable us to detect really strong an promising candidates. These 
strong candidates can then be extensively investigated in the animal model and thus may lead to the development 
of potential novel compounds. 
4.2.1 Heterogeneity in antidepressant treatment outcome can be modeled in mice 
While many patients respond well to the currently available antidepressants, a significant 
number of patients do not show an adequate response to the treatment, show remaining 
symptoms or the patients relapse (Trivedi et al., 2006; Carter et al., 2012). Clinical 
studies, such as the STAR*D study have demonstrated that patients can be divided into 
remitters or 'good responders' and non-remitters or 'poor responders' to a prescribed 
therapy. Furthermore, it could be shown in clinical studies that most of the time, treatment 
strategies are based on a trial and error principle (Fabbri et al., 2013) and the longer the 
patients are treated the less chance they have to remit (Trivedi et al., 2006). These 
findings from clinical studies highlight the extensive variety in antidepressant treatment 
outcome. To-date, in preclinical research there is no available animal model able to 
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distinguish between good and poor treatment responders according to a behavioral 
readout. Our novel experimental design enables us to detect good and poor treatment 
responders, according to their performance in the FST. More importantly we are to 
establish a connection between clinical and preclinical findings.  
The investigation of extreme groups has already been successfully performed in the field 
of stress research. Specifically, it has already been shown that not all animals respond in 
the same way to a stressful stimulus. Schmidt and colleagues subjected a large number of 
animals to a chronic social stress paradigm to demonstrate that some animals recover 
quickly from the stress procedure, whereas others do not. According to basal 
corticosterone levels measured 5 weeks after the stress procedure, stressed animals 
were classified either as 'vulnerable' or 'resilient'. With this experimental design, they 
could demonstrate that individual stress susceptibility can be detected when using a large 
animal cohort (Schmidt et al., 2010). However, with respect to antidepressant treatment 
response, nobody has yet followed such an experimental design. Our novel experimental 
approach is a promising, new attempt in order to shed light on treatment response and 
thus represents an innovative approach to investigate novel targets mediating individual 
responsiveness to antidepressant treatment. 
4.2.2 Is the FST a suitable readout parameter for antidepressant response? 
The FST is one of the most commonly used behavioral tests to screen antidepressant 
activity in rodents (Cryan et al., 2002). Thus, we postulated that the FST, is a valid tool to 
detect individual antidepressant treatment responses within a large group of animals. 
Porsolt introduced the FST in rats in the late 1970s to assess antidepressant activity in 
preclinical animal models (Porsolt et al., 1977a). Since that time the FST is widely used to 
investigate antidepressant activity for novel and already known compounds, in order to 
detect depressive-like behavior and stress coping strategies in rodents (Cryan et al., 
2002; Lucki, 1997). The test is based on establishing an inescapable situation for the 
rodent. The initial escapable-orientated motivation develops into an immobile posture 
(Cryan et al., 2002). This immobile posture is considered on the one hand, as a failure to 
pursue escape-directed behavior, and on the other hand, is seen as passive behavior that 
disengages the animal from active forms of coping with stressful stimuli (Lucki, 1997). In 
general, antidepressants increase escape-directed behavior and prolong the onset of 
immobility behavior (Cryan et al., 2002). However, the FST is debated controversially in 
the literature. Some studies criticize that acute antidepressant treatment evokes 
  DISCUSSION 
 
100 
behavioral effects in the FST, although acute antidepressant treatment has no effect in 
clinical studies (Cryan et al., 2002). The FST should be seen more as a reliable behavioral 
tool, which is not necessarily a model for depression but rather for antidepressant 
treatment outcome (Petit-Demouliere et al., 2005). Considering the identification of 
individual antidepressant treatment outcomes was one of the main aims of this thesis, the 
FST was the most suitable tool. Furthermore, to ensure that the behavioral readout 
describes real antidepressant response, we performed two FSTs, one before and one 
after the antidepressant treatment. This repeated testing enabled us to investigate 
whether differences in the treatment response of animals could be due to preexisting, 
inherent characteristics or due to a real pharmacological treatment effect. With this test, 
we were able to show that the preexisting inherent characteristics do not correlate with 
those arising after antidepressant treatment.  
4.3 Genes and gene networks mediating an early onset of antidepressant 
response 
According to findings from clinical studies, there is a subset of patients that respond to an 
antidepressant treatment at an early stage, i.e. after 2 weeks of treatment (Taylor et al., 
2006; Nierenberg et al., 2000; Entsuah et al., 1998). Although all animals were treated 
and handled in the same way, we were also able to detect a large behavioral variation 
within the animals as indicated in the FST. After identifying good and poor responders, we 
investigated differences in their gene expression profile. Analysis of the brain microarray 
experiment revealed 87 differentially regulated genes between good responders and 
vehicle-treated animals, while there were no significant differences between good and 
poor treatment responders. 
4.3.1 Subchronic paroxetine treatment enables the identification of an expression 
profile signature predicting antidepressant response in patients 
In clinical studies, blood expression profiling has become a more frequently used 
technique to investigate genetic alterations following various treatment and/or 
environmental contexts in clinical studies. Therefore, we investigated the influence of 
subchronic paroxetine administration on gene expression alterations in peripheral blood in 
order to increase the translational value of our approach.  
After statistical correction, we found a robust gene regulation effect of 259 transcripts 
when comparing RNA extracted from blood of good and poor treatment responders. 
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Interestingly, there was no overlap of significantly regulated genes in the periphery and 
the brain. This suggests that gene expression changes measured in the patients' blood 
are largely independent of gene expression alterations in the brain. To-date, there are few 
studies comparing the gene expression profile of the peripheral blood with that of the 
CNS. Sullivan and colleagues have shown in clinical studies, that whole blood share 
significant gene expression similarities with various human brain tissue, at least at the 
level of the transcriptome. Furthermore, when investigating candidate genes relevant to 
schizophrenia, they were able to show that approximately half of the genes were 
expressed in both whole blood as well as prefrontal cortex tissue (Sullivan et al., 2006). 
However, this study has its limitations: firstly, the human data set shows a high level of 
genetic heterogeneity, which makes it even harder to detect common genes. Secondly, 
there is always a general methodological problem when it comes to post-mortem tissue 
(Sullivan et al., 2006; Witt et al., 2013). Witt and colleague also compared the gene 
expression profiles of blood, hippocampus and prefrontal cortex in genetically identical 
rats under baseline conditions. Here, they could show that, nearly all genes expressed in 
the blood tissue are also expressed in at least one brain tissue. However, the authors 
clearly state that it would be desirable to investigate the co-expression of genes in blood 
and brain tissue after a certain form of challenge or treatment (Witt et al., 2013). The 
current findings reported here, are not in line with the afore mentioned studies. We were 
unable to detect any overlap between genes regulated in blood and hippocampal tissue in 
subchronically-treated male DBA/2J mice challenged to a FST. Given the importance of 
the comparability of gene expression profiles in blood and brain tissue in neuropsychiatric 
research (Witt et al., 2013), the need for more studies is inevitable.  
In order to assess the relevance of the mouse gene expression transcripts for 
antidepressant response differences in humans, we tested their predictive ability to 
classify response status in a human sample. Repeated gene expression measures from 
the patients at baseline at 2 and 12 weeks after the treatment onset was available. 
Therefore we were interested as to whether differences in gene expression are able to 
predict antidepressant response. Interestingly, we detected differences in expression 
profiles from baseline to week 12 of the human-orthologues that allowed us to predict the 
response status (percent change in HDRS-17 from baseline to week 12) with an accuracy 
of 84% in the human sample. To our knowledge, this is the first study that has been able 
to show such a prediction rate in a translational approach. These findings bring us a step 
closer to predict antidepressant treatment response at an early stage during 
antidepressant treatment. In order to better understand, how the detected genes are 
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connected to each other, we performed further analyses to detect common transcription 
factors. Using the ENCODE ChIP-Seq Significance Tool, we identified the CTCF one of 
the candidates that was enriched in our data set. The effect of this transcription factor was 
replicated in the human ortholog sample. Specifically, 145 of the 236 genes were similarly 
regulated by CTCF in the human data set. Thus, the genes identified in our analysis are 
closely linked by CTCF transcription factor regulation, indicating a common mechanism 
(Figure 43). While CTCF hosts many cellular roles, one study implicated its role in the 
regulation of serotonin receptors, thereby linking this transcription factor to a 
predisposition to affective disorders (Phillips and Corces, 2009). The strong enrichment of 
our gene set for this transcription factor supports the role for possible activity of this factor 
in treatment response for major depression. According to the literature, CTCF seems to 
be a very promising candidate, playing an important regulatory role for numerous genes. 
However one has to keep in mind that approximately 14000 - 40000 binding sites for 
CTCF have already been identified genome-wide (Phillips and Corces, 2009). By 
identifying this common transcription factor, further studies should be performed in order 
to investigate how this transcription factor is mediating antidepressant responsiveness in 
our mouse model and more importantly, investigate how relevant CTFC is as a key 
modulator to the gene set detected in our translational approach. 
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Figure 43: Translational approach enables us to detect common transcription factors. By using this translational 
approach we were able to detect a gene set, which is regulated in the mouse peripheral blood after 14d of 
paroxetine treatment. After the integration of the mouse data in the human dataset, we were able to detect 
differences in gene expression profiles in the human samples from baseline to week 12 that allow us to predict the 
response status with an accuracy of 84% in the human samples. Further investigations also identified CTCF, a 
transcription factor, as being enriched in both the human and mouse data set.  
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4.3.2 Subchronic paroxetine treatment regulates a distinct gene network in the 
brain 
In order to gain a better understanding of the biological connections amongst the various 
detected genes in the brain, a pathway analysis was performed, based on information 
derived from literature-based interactions between proteins, small molecules and cellular 
processes (Webhofer et al., 2011). Interestingly, we were able to detect a gene network 
comprising 15 of the 87 differentially regulated genes. At present, there is little known 
about this gene network in the literature. Interestingly, immune-related genes such as 
Cxcl12 or Il-16, and structural genes such as Gfap and Vim, are highly represented in the 
detected network. There is growing evidence that an altered immune response is an 
important aspect of mood disorders (Friedrich, 2014). Cytokines as well as chemokines 
are hormonal mediators of the immune response and play a crucial role in the 
neuroendocrine system. Cytokines are small signaling molecules, which are secreted by 
various cell types, including astrocytes, microglia, lymphocytes (Arisi, 2014). It has been 
demonstrated that an elevation of circulating proinflammatory cytokines, namely IL-6 and 
tumor necrosis factor alpha, is a characteristic feature in a subset of depressed patients 
(Villanueva, 2013; Dunn, 2006). Proinflammatory cytokines do not only contribute to the 
innate immune response and inflammation, but they also have relevant neuroendocrine 
and metabolic effects, specifically affecting neurotransmitter metabolism and neural 
plasticity (Villanueva, 2013). We could show that subchronic antidepressant treatment 
regulates the proinflammatory cytokines. More specifically, we found that subchronic 
paroxetine exposure significantly downregulated Il-16 mRNA levels. This finding is in line 
with previous findings, showing that administration of cytokine Il-6 induces depressive-like 
behavior in rodents and fluoxetine treatment is able to neutralize this effect (Sukoff Rizzo 
et al., 2012). Besides Il-16, we also detected the chemokine Cxcl12. Chemokines are 
small secreted proteins with chemoattractant properties, meaning that they can attract and 
activate immune and non-immune cells (Réaux-Le Goazigo et al., 2013) and are thus 
acting as neuromodulators (Adler et al., 2005). Currently, the well-established roles of 
Cxcl12 all converge on immune functions, however, more and more reports also identify 
Cxcl12 as an important player in the CNS (Réaux-Le Goazigo et al., 2013). A potential 
role of Cxcl12 in mood disorders is strengthened by the fact that Cxcl12 is also involved in 
neuroprotection, neurogenesis, regeneration and axon guidance. Interestingly, Cxcl12 
seems to interact with Stat3, a gene also detected in the gene network. It has been 
demonstrated that higher expression of Cxcl12 leads to higher Stat3 phosphorylation 
(Shen et al., 2013). Shen and colleagues were able to show that pharmacological 
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blockade of Stat3 activity inhibited Cxcl12-triggered Stat3 phosphorylation (Shen et al., 
2013). Furthermore, studies could show that Stat3 is activated in various cell types by a 
number of cytokines, such as IL-6 and TGFα (Takeda et al., 1997). These cytokines are in 
turn implicated in triggering reactive astrogliosis (Balasingam et al., 1994; Klein et al., 
1997; Levison et al., 2000; Rabchevsky et al., 1998). Herrmann and coworkers have 
shown that Stat3 is a critical factor for certain aspects of reactive astrogliosis (Herrmann 
et al., 2008) and thus is also a very interesting candidate for future investigation. 
Besides immune-related genes, structural proteins namely glial fibrillary acidic protein 
(Gfap) and vimentine (Vim) were also regulated after subchronic antidepressant 
treatment. There is growing evidence in the field of depression that structural molecules 
play an important role in the pathology of depression as well as in antidepressant 
treatment response. In 2008, Sillaber and colleagues had already shown a significant 
upregulation of Gfap and Vim following chronic paroxetine treatment in male DBA mice, 
which is in line with our findings (Sillaber et al., 2008). Human post mortem studies have 
furthermore shown that GFAP proteins are significantly reduced in depressed patients, 
which strengthens the involvement of glial (dys)-function in mood disorders (Fatemi et al., 
2004). Gfap is nearly exclusively expressed in astroytes and is involved in gliosis, 
neurodegeneration, neuroregeneration and neurogenesis (Fatemi et al., 2004; Sillaber et 
al., 2008). Astrocytes are structural and trophic supporters of neurons and play a key role 
in the CNS immune response, as well as a role in the clearance of ions and 
neurotransmitters (Allen and Barres, 2005; Araque, 2006). Some studies have 
demonstrated that astrocytes play a role in neural progenitor cells during development as 
well as in the mature CNS and promote neurogenesis (Goldman, 2003; Song et al., 2002). 
Additionally, it could be shown that 28d of antidepressant treatment is able to prevent 
stress-induced decreases in astrocyte number. This finding supports the hypothesis that 
dysregulation of glial cells may be involved in the pathophysiology of mood disorders 
(Sillaber et al., 2008; Czéh et al., 2005; Manev et al., 2003). 
In summary, although selected connections between antidepressant-regulated genes 
have been identified, the complete picture of this antidepressant-induced gene network is 
still not clear. To advance the current understanding in regards to the individual role of 
different genes in antidepressant response, further investigations are required. 
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4.4 Gene expression profiling in the hippocampus following chronic 
antidepressant treatment 
In a second study, we were interested in examining the differences between good and 
poor responder after chronic paroxetine treatment, as most depressed patients start 
responding to pharmacological treatment after at least 4 weeks of antidepressant 
administration (Wisniewski et al., 2009; Trivedi et al., 2006; Rojo et al., 2005; Nemeroff 
and Owens, 2002). Here, we aimed to identify novel genes differently regulated between 
good and poor responders. After the identification of the various responder subgroups, an 
unbiased microarray approach was conducted with the tissue derived from the chronically 
treated animals. After statistical analysis of the Illumina microarray chip, 30 genes were 
found to be differently regulated between vehicle treated animals and good responders. 
Although we did not detect a significant difference between good and poor treatment 
responders, a clear treatment effect was evident. Out of the 30 differently regulated 
genes, 12 genes were selected for further validation. With a validation rate of 75% we 
were able to validate a significant number of the selected candidates confirming the 
validity of our results. In the following section, select candidates are discussed in more 
detail: 
ActivinA receptor type 1c, also known as Acvr1c or Alk-7, represents one of the genes 
that was significantly upregulated in the hippocampus of good responders. Activins belong 
to the transforming growth factor-β (TGFβ) superfamily which are now well-known as 
multifunctional regulatory proteins (Werner and Alzheimer, 2006). Besides their role in 
development and hormonal regulation, previous studies have also demonstrated that 
Activins play an important functional role in tissue repair and have been identified as an 
important target in various inflammatory diseases, including brain-related inflammatory 
diseases (Werner and Alzheimer, 2006). Acvr1c, as a member of the Activins, is a growth 
factor-associated gene involved in the survival and differentiation of adult neuronal cells 
(Miller et al., 2007). Furthermore, it is part of the Activin/Inhibin signaling cascade, which 
was previously found to be involved in antidepressant-like properties (Ganea et al., 2012). 
In the study conducted by Ganea and colleagues, Activinβ A exerted acute 
antidepressant-like effects when directly administered to the hippocampal dentate gyrus. 
Collectively, these findings support a potential role of Acvr1c in antidepressant treatment 
outcome and thus make it as a suitable candidate for further studies.  
In addition to its effects of Acvr1c receptor activity, we found that chronic antidepressant 
treatment also affects other genes involved in the inflammatory system, which already 
DISCUSSION   
 
107 
came up as a key system following subchronic treatment. One of these genes was the 
complement component 1, q subcomponent-like 2 (C1ql2). C1ql2 is a protein-coding gene 
and is part of the complement pathway, which is involved in the immune response system. 
C1q is a target recognition protein of the classical complement pathway. It's crucial role 
involves the clearance of pathogens and apoptotic cells (Kishore et al., 2004). C1q is also 
involved in a number of immunological processes such as phagocytosis of bacteria, 
neutralization of retroviruses, cell adhesion as well as modulation of dendritic cells 
(Kishore et al., 2004). Complement proteins are localized in the developing central 
nervous system synapses. They are present during a period of active synapse elimination 
and are crucial for normal brain wiring. It has been shown that their role in the brain is 
similar to their function in the immune system: the clearance of cellular material. C1q can 
be divided into two subfamilies: C1q-like proteins and cerebellin-like proteins. While it is 
known that cerebellin-like proteins are essential trans-neuronal regulators of synaptic 
integrity in the cerebellum (Iijima et al., 2010), not much is known about the role and 
function of C1q-like proteins and C1ql2 in particular. During adulthood, C1ql2 is only 
expressed in the dentate gyrus formation of the hippocampus (Iijima et al., 2010). 
Furthermore, there is evidence that C1ql2 is mainly expressed in neurons and to a lesser 
extent in glia cells during adulthood (Iijima et al., 2010). At present, there are no reports 
for an involvement of C1ql2 in depression. However, the link between depression and 
inflammation is highly recognized in the field of depression (Dantzer et al., 2008). 
Furthermore, the hippocampus is a main target region in depression research and thus 
the unique expression pattern of C1ql2 during adulthood strengthens its potential as a 
candidate gene in mental disorders. 
Serpinf1 marks another gene that was detected in the microarray analysis. Serpinf1 
belongs to the serpine family of peptidase inhibitors and is also known by the name 
pigment epithelium-derived factor (PEDF). During development, Serpinf1 is essential for 
the development of the neural retina (Steele et al., 1993). Bilak and colleagues could 
show that Serpinf1 is a neurotrophic factor, which is broadly distributed in the central 
nervous system. It has been suggested, that this factor could have pleiotrophic, 
neurotrophic and neuroprotective effects on non-retinal neurons (Bilak et al., 1999). 
Serpinf1 is a 50kDa, secreted glycoprotein, expressed in a variety of tissue types. For 
instance, adipocytes also secrete Serpinf1 and it thus showed promise as a candidate 
gene in obesity-induced insulin resistance (Böhm et al., 2012; Crowe et al., 2009). 
Furthermore, it was shown that Serpinf1 promotes neuronal survival, differentiation and 
potent inhibition of angiogenesis (Tombran-Tink et al., 1991; Tombran-Tink and 
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Barnstable, 2003). In 2008, Miller and colleagues were one of the first to show a potential 
link between Serpinf1 and antidepressant treatment. They could demonstrate that 
Serpinf1 is upregulated after chronic fluoxetine treatment, which is in line with our current 
finding. The fact that Serpinf1 is responsive to antidepressant treatment and is 
furthermore known to promote proliferation of neuronal progenitor cells, makes it to a very 
promising candidate in antidepressant treatment outcome (Miller et al., 2007). 
Taken together, after chronic paroxetine treatment, we were not able to find significant 
differences, at least on mRNA level, between good and poor treatment responders. Our 
main gene expression differences were detectable between vehicle treated animals and 
good responders. However, to our knowledge, we were the first to examine individual 
antidepressant response after chronic treatment in DBA/2J mice. Thus our study provides 
novel, interesting and promising targets for further antidepressant studies.  
4.5 Time course of gene expression regulation during antidepressant 
treatment in the mouse hippocampus  
Interestingly, more genes were regulated by subchronic paroxetine treatment compared to 
chronic treatment, indicating that at the beginning of the treatment period a large cluster of 
genes are regulated. Our data suggest that following a 4-weeks treatment period, certain 
genes return to baseline expression levels, whereas others remain responsive to the 
ongoing treatment either through direct effects of antidepressant activity or rather 
indirectly as a result of activation of previous cascades. As the number of regulated genes 
significantly varies between the two different time points, the question arises as to whether 
there is an overlap between subchronic and chronic treatment. When comparing the gene 
expression profile of the two treatment time points, we can identify an overlap of 15 genes 
(Table 6) representing genes that were differently regulated following both treatment 
intervals. 
Genes integral to immune function (C1ql2), neurogenesis (Sox11) and receptor activity 
(Acvr1c, Adra2c, Drd1a) are among the regulated genes.  
Sox11 was identified as one of the genes regulated after both treatment durations, 
potentially signaling an important role for Sox11 in mediating antidepressants' mechanism 
of action. This finding encouraged us to consider Sox11as an interesting candidate gene 
for further investigations. Sox11 is a member of the Sox gene family that has been well 
characterized regarding its expression pattern in the developmental nervous system and 
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its role in neurogenesis, neural cell survival and neurite outgrowth (Bergsland et al., 
2006). During development, Sox11 is highly expressed in developing sensory neurons 
(Jankowski et al., 2009) and in brain areas that are important for neuron differentiation 
(Kuhlbrodt et al., 1998). Importantly, Sox11 gene expression is regulated both spatially 
and temporally (Wilson and Koopman, 2002), meaning that its expression is reduced in 
late stages of gestation and remains low in adult neurons (Jankowski et al., 2009). 
Developmental studies have shown that Sox11 plays a crucial role in embryo 
development. This is further demonstrated in Sox11 knockout studies, which have 
revealed that total Sox11 knockout mice are embryonically lethal, whereas its partial 
depletion results in various craniofacial and skeletal malformations, asplenia and 
hypoplasia of the lung and stomach, altogether suggesting an important role of Sox11 in 
tissue remodeling. These findings are in line with the human situation (Sock et al., 2004). 
Jankowski and coworkers provide evidences that Sox11 plays a central role in regulating 
processes, which in turn promote neurite growth as well as neuron survival (Jankowski et 
al., 2006). Studies could show that the basal level of Sox11 expression is lower during 
adult hood compared to the developmental stage. However, it was found to be 
upregulated after nerve injury and was associated with injury-induced neuritogenesis 
(Elliott et al., 2003; Tanabe et al., 2003). 
4.6 Sox11- a transcription factor and its putative role in emotional behavior 
Only very little is known about a putative role of Sox11 in modulating emotional behavior.  
4.6.1 Paroxetine is leading to a robust regulation of Sox11  
We, therefore, continued to dissect the role of Sox11 in the neurobiology underlying 
antidepressants' mechanism of action in detail. We were able to show a significant 
upregulation of Sox11 mRNA levels, especially in the hippocampal DG, after subchronic 
and chronic paroxetine treatment. These findings are in line with previous findings, where 
chronic paroxetine treatment lead to a upregulation of Sox11 mRNA levels in DBA mice 
(Sillaber et al., 2008). We found Sox11 mRNA levels already upregulated as early as 14d 
(i.e. after subchronic) of treatment. Interestingly, we did not see any changes in Sox11 
expression following an acute antidepressant administration, indicating that the 
paroxetine-induced time course of Sox11 induction corresponds with the delayed onset of 
action of antidepressant effects in the clinical setting. Sox11 has been well characterized 
regarding its expression pattern in the neurogenic niche and its role in neurogenesis, 
neural cell survival and neurite outgrowth (Bergsland et al., 2006). In the adult mouse 
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Sox11 is mainly expressed in the DG formation of the hippocampus (Haslinger et al., 
2009). There is a large body of literature supporting the idea that stimulation of 
neurogenesis in the adult brain could be a crucial step in the successful treatment of 
depressive disorders. For example, various studies have shown an interplay between 
antidepressants and neurogenesis (Braun and Jessberger, 2014; D'Sa and Duman, 2002; 
Sahay and Hen, 2007). However the effect of antidepressant treatment on neurogenesis 
are mainly detected after a chronic administration (Malberg et al., 2000).  
We were also interested as to whether the induction of Sox11 is a general antidepressant-
induced phenomenon, or whether it is rather exclusively triggered by SSRIs. Therefore, 
we performed a chronic treatment with reboxetine, a NERI. In this experiment, we did not 
find a significant difference in Sox11 gene expression levels between vehicle-treated 
animals and reboxetine-treated animals. These findings suggest that Sox11 upregulation 
is specific for SSRIs in general and paroxetine in particular. It is hypothesized that the 
antidepressant effect on neurogenesis is mediated by serotonergic regulation of 
intracellular signaling mechanisms that consequently upregulate transcription and growth 
factors and are thus involved in neuron proliferation (Duman et al., 2001). In support of 
this hypothesis, Santarelli and colleagues treated mice for three weeks with fluoxetine and 
found a significant upregulation of cell proliferation (70%) in the dentate gyrus. In a follow-
up experiment they used 5-HT1Areceptor knockout mice and the effect was gone 
(Santarelli et al., 2003). These results further support our findings that serotonergic 
modulations especially lead to changes in cell proliferation and thus neurogenesis. Hence, 
it is not surprising that transcription factors or genes that are involved in cell proliferation 
are more responsive to serotonergic antidepressants compared to antidepressants based 
on noradrenergic transmission. 
4.6.2 Sox11 overexpression reduces anxiety-related behavior, but is not 
influencing neurogenesis 
Considering that Sox11 was upregulated after chronic SSRI treatment and chronic 
antidepressant treatment lead to a less depressive-like phenotype in the FST, we 
hypothesized that viral overexpression of Sox11 may also lead to a less depressive-like 
phenotype, as reflected in the FST. However, we did not detect any behavioral alteration 
in the FST following a viral overexpression of Sox11.  
David and colleagues demonstrated that a fluoxetine-induced FST phenotype is 
independent of hippocampal neurogenesis (David et al., 2009). Thus, if the predominant 
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function of Sox11 in the DG is neurogenesis-related (Haslinger et al., 2009; Haslinger et 
al., 2009), an effect of Sox11 OE on the FST phenotype would be unlikely.  
However, we could clearly show that overexpression of Sox11 significantly reduced 
anxiety-related behavior compared to the vehicle-treated empty control animals. Besides 
its cognitive function, the hippocampus is also involved in regulating emotional behavior, 
including anxiety. Various studies have demonstrated a link between the hippocampus, 
neurogenesis and anxiety. For instance, Revest and colleagues could show that a 
decrease in adult-born neurons increases anxiety-related behavior (Revest et al., 2009). 
More specifically, they demonstrated that an impairment in neurogenesis is associated 
with an increased avoidance of novel and potentially threatening environments. Two other 
studies are in line with Revest et al., however they directly manipulated various target 
genes like Activin and TrkB receptor (Ageta et al., 2008; Bergami et al., 2008). As Sox11 
is involved in cell proliferation (Haslinger et al., 2009; Wegner, 2011) and thus directly 
and/or indirectly involved in neurogenesis, our results are fitting well to the previous 
findings. We were able to induce a less anxious phenotype by increasing Sox11 
expression. As we do not see any changes in the FST, we can ensure that the effect is 
selective for anxiety-related behavior. As reboxetine treatment modulated neither anxiety-
related behavior nor the expression of Sox11 mRNA, these findings support our 
hypothesis that Sox11 could be involved in shaping anxiety-related behavior.  
To further investigate whether the reduction in anxiety-like behavior might be 
accompanied by changes in cell proliferation, we performed a cell proliferation study. 
Therefore, we artificially overexpressed Sox11 via an AAV virus injection and investigated 
neurogenesis and cell proliferation in these animals. Animals were injected for three 
consecutive days with a 100mg/kg pulse of BrdU. This timeline was chosen, as it has 
been shown in previous studies, that DBA/2J mice show very little baseline neurogenesis. 
The rare of neurogenesis rate is highly heritable but also highly variable among the 
different inbred mouse strains (Kempermann et al., 2006). For example, it has been 
shown in a previous study, comparing four inbred mouse strains, that DBA/2J mice show 
a cell survival rate of 19% 4 weeks after the BrdU administration. In the same study, they 
additionally demonstrated that DBA/2J mice produce significantly fewer neurons 
compared to the other mouse strains under examination but significantly more astrocytes 
(Kempermann and Gage, 2002). To investigate cell proliferation, select animals were 
killed 2h or 28d after the last BrdU injection. When investigating differences in BrdU-
positive cells we did not find any differences between the two groups. Despite the known 
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role of Sox11 in neurogenesis, we did not observe an effect of Sox11 OE on cell 
proliferation or maturation. It has been shown that chronic stress reduces neurogenesis by 
modulating cell proliferation and maturation rate, whereas antidepressants are able to 
reverse such stress-induced effect (Braun and Jessberger, 2014; David et al., 2009; 
Duman and Monteggia, 2006; Santarelli et al., 2003). The lack of this effect in our study 
could be due to the stage-specific expression of Sox11 in cells of the adult neurogenic 
lineage (Haslinger et al., 2009). This means that Sox11 expression is associated with a 
downregulation of Sox2 and with the onset of DCX expression, an early neuronal lineage 
marker (Brown et al., 2003). The stage-specific restriction of Sox11 corresponds with the 
transient expression during embryonic development and more specifically embryonic 
neurogenesis (Bergsland et al., 2006; Hargrave et al., 1997), which suggests that Sox11 
controls similar stage-specific processes during embryonic development and adult 
neurogenesis (Haslinger et al., 2009). At present, Sox11 regulation in the adult 
neurogenic lineage remains unknown (Haslinger et al., 2009) and it is still unclear whether 
Sox11 itself is directly responsible for neurogenesis. Some studies suggest that Sox11 
plays an important role in adult neurogenesis (Sha et al., 2012; Jankowski et al., 2006; 
Haslinger et al., 2009), yet to our knowledge nobody has performed a BrdU experiment 
with Sox11 OE mice. Our experiment thus sheds light on this topic. We have shown that 
the viral overexpression of Sox11 itself is not sufficient to increase cell proliferation and 
cell maturation rates although we were able to detect behavioral phenotypes similar to 
those ascribed to alterations in neurogenesis. Although the overexpression of Sox11 
leads to an altered behavioral phenotype, the cellular explanation for this behavioral 
phenotype is not as obvious as first speculated. One explanation is founded on the stage-
specific expression of Sox11 in neurogenic lineage. We performed viral overexpression of 
Sox11 and then waited for 4 weeks in order to achieve robust overexpression of Sox11. 
As Sox11 expression is associated with the downregulation of Sox2 and with the onset of 
DCX expression (Brown et al., 2003), it is possible that we targeted the wrong time 
window to detect differences in neurogenesis due to viral Sox11 OE. Alternatively, the 
involvement of Sox11 in neurogenesis is not directly regulated via Sox11. If this would be 
the case, manipulation of Sox11 upstream targets are needed to potentially evoke robust 
neurogenesis effects on a cellular level. Nonetheless, further investigations are indeed 
necessary in order to find a cellular explanation for the anxiety-like phenotype. 
DISCUSSION   
 
113 
4.6.3 Sox11 knockdown does not influence antidepressant response but leads to 
a higher mortality rate 
As Sox11 OE decreases anxiety-related behavior, we were also interested as to whether 
a knockdown of Sox11 is able to produce a more anxious phenotype and whether or not 
paroxetine would be able to reverse this effect. Surprisingly, hippocampal knockdown of 
Sox11 in adulthood, resulted in higher mortality rates in DBA/2J mice compared to the 
control group. It is known that Sox11 plays a crucial role during development and is 
essential for normal organ development (Sock et al., 2004). However, to-date there is 
nothing known about the role of a partial knockdown or knockout of Sox11 during 
adulthood. In our experimental animals we observed convulsive poses in the homecage in 
the late afternoon (n=3) and while weighing the animals (n=2). These observations led us 
to speculate that the high mortality rate in the Sox11 KD animals might be due to epileptic 
seizures. There is growing evidence in the literature that genes, which are involved in 
neurogenesis, may also play a significant role in epilepsy (Elliott et al., 2003). Therefore, 
further investigations are needed to investigate the role of Sox11 KD in adult DBA/2J mice 
in terms of epileptic seizures. Moreover, the mortality rate should be kept in mind when 
interpreting the behavioral parameters. In contrast to our previous experiments, we 
observed a paroxetine-induced hyperactivity. Hyperactivity resulting from antidepressant 
treatment is controversial with mixed findings in the literature. Some studies have shown a 
significant increase in basal locomotor activity following antidepressant treatment whereas 
others have shown no effect (Dulawa et al., 2004; Prut and Belzung, 2003). In the current 
experiment, the previous surgery may have confounded the results, and may possibly 
underlie the animals' hypersensitivity to paroxetine-induced hyperactivity. Interestingly, we 
did not observe an effect of Sox11 manipulation on the FST behavior. By contrast Sox11 
manipulation has a clear, directional effect on anxiety-like behavior. Specifically 
hippocampal overexpression of Sox11 promotes a reduced anxiety-like phenotype, 
whereas hippocampal knockdown of Sox11 suitably increased anxiety-related behavior in 
the DaLi, an effect that was independent of the treatment. These findings support a pivotal 
role of Sox11 in modulating anxiety-related behavior. To deliver a plausible explanation for 
this is not possible at the moment. Further investigations, at a cellular and behavioral 
level, are needed in order to advance our current understanding of the function and 
signaling cascades of Sox11. 
At present, we can conclude that Sox11 plays an essential role during adulthood and is a 
potential novel target for modulating anxiety-related behavior.  
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4.7 Summary 
Major depressive disorder is one of the most common mental disorders. It is a very 
complex and multifactorial psychiatric disease, which affects up to 20% of the general 
population (Kessler et al., 2005). Furthermore, unipolar depressive disorders pose an 
immense burden on society and the WHO ranked depression as the fourth leading cause 
of disability (Murray and Lopez, 1996; Rubinow, 2006). Additionally, bipolar disorders 
(episodes of major depression and mania) and anxiety are two diseases that most 
frequently overlap diagnostically with depression (Flint and Kendler, 2014). Despite the 
immense research that has been ongoing over the past decades, the pathophysiology of 
depression as well as the neurobiology underlying the surprisingly high heterogeneity in 
antidepressant treatment response are still largely unknown. 
The present study therefore aimed to identify novel targets mediating an individual 
antidepressant response in mice. Furthermore, we attempted to translate these findings to 
the clinical situation in order to detect novel biomarkers for antidepressant treatment 
outcome. As a first step, we investigated the pharmacological profile of paroxetine in order 
to define the minimum effective dose for DBA/2J mice. To our knowledge, this is the first 
study to extensively investigate the pharmacological profile of paroxetine in mice. 
Furthermore, the current thesis provides a compelling basis for the involvement of Sox11 
in anxiety-related behavior. We extensively investigated the function of Sox11 under 
various antidepressant substances, different treatment durations as well as after genetic 
manipulation to provide strong evidence that Sox11 is a promising target for anxiety-
related disorders. Previous studies have ascribed a potential role for Sox11 in 
neurogenesis (Haslinger et al., 2009; Mu et al., 2012a). Nevertheless, by genetically 
manipulating Sox11, we have shown that Sox11 alone is not sufficient to directly influence 
the neurogenesis rate in DBA/2J mice. Regardless, Sox11 is a very interesting candidate 
when investigating anxiety-related behavior. 
To address the problems of the delayed onset of antidepressant action, we aimed to 
identify novel targets mediating an early antidepressant response. Therefore, we 
performed a subchronic paroxetine treatment and investigated alterations in gene 
expression profiles in the periphery and the brain. In a next step, we integrated our 
findings with human data in order to assess whether such gene expression profiles are 
able to predict antidepressant response status in the human sample population. To our 
knowledge, this is the first study that was able to show such a prediction in antidepressant 
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response using a translational approach. These findings allow us to predict at an early 
stage, i.e. two weeks after treatment onset, whether the patient will show an appropriate 
response after 12 weeks of antidepressant treatment (Figure 44). Moreover, we were able 
to identify common transcription factors that seems to play a role in antidepressant 
treatment response. 
 
Figure 44: Achievements of this thesis. This experiment approach was able to solve some basic but important 
questions in depression research. However these data needs further investigations and some questions still need 
to be addressed. 
This study provides essential, novel information regarding gene regulation by 
antidepressant treatment and is therefore a good starting point for the identification of 
novel biomarkers mediating individual antidepressant response. We were able to shed 
new light on the field of antidepressant treatment outcome and more specifically, on early 
antidepressant response. Furthermore, our translational approach enabled us to translate 
our findings from mice to men and thus provides a good basis for further research. 
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Alltag geflohen sind. So groß und bedeutend sich diese Arbeit momentan anfühlt, so 
größer und bedeutender ist das was uns beide verbindet. 
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8 Assertion (Erklärung) 
Hiermit versichere ich eidesstattlich, dass ich die vorliegende Dissertation selbstständig 
und nur mit den angegebenen Quellen und Hilfsmitteln angefertigt habe. Alle 
Ausführungen, die wörtlich oder sinngemäß übernommen wurden, sind als solche 
gekennzeichnet. 
Des Weiteren erkläre ich, dass ich nicht anderweitig ohne Erfolg versucht habe, eine 
Dissertation einzureichen oder mich der Doktorprüfung zu unterziehen. Die vorliegende 
Dissertation liegt weder ganz, noch in wesentlichen Teilen einer anderen 
Prüfungskommission vor. 
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